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Tissue engineering and regenerative medicine represent a dynamically developing field of 
medicine. It aims to restore, maintain or improve the function of a tissue or an organ. Its 
principles emerge also in the tissue engineering of the skin. Skin represents a barrier protecting 
the human body against the outer environment. With the ageing of the population, unhealthy 
life style choices and the increasing incidence of the associated metabolic diseases, chronic 
wounds are becoming a worldwide issue and novel, effective wound dressings and/or skin 
substitutes are needed. 
One of the most important factors in tissue engineering/regenerative medicine is the choice 
of scaffolding system. The scaffold should be nontoxic, biodegradable, should promote 
migration and adhesion of the cells of interest, and subsequently allow their expansion and 
extracellular matrix synthesis. Very promising scaffolding systems are nano- and microfibrous 
scaffolds fabricated using electrospinning and centrifugal spinning. These techniques allow 
further functionalization of the scaffolds with bioactive molecules. As a simple and cost-effective 
source of bioactive molecules, platelets may be used. The unique characteristics of platelets 
may be used in many forms with varying mechanical properties and content of the bioactive 
molecules, depending on the method of preparation of the platelet derivatives. 
This work aims to investigate the effects of platelet-derived molecules in skin tissue 
engineering and to develop sophisticated and fine-tuned drug delivery systems, as well as 
systems with clear potential of clinical translation. 
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2 LITERATURE REVIEW 
2.1 Skin 
Skin is the largest organ of the human body, with the surface of 1.4–2.0 m2 representing 
approximately 16% of body weight1,2. Its thickness varies greatly depending on the function and 
area of the body from about 0.5 mm to up to 4 mm3. To the most important functions of the skin 
belongs its barrier function. It also plays role in electrolyte and fluid balance, provides protection 
against microbiological colonization, prevents photodamage by ultraviolet radiation, is involved 
in vitamin D synthesis and contains sensory receptors enabling sensation of touch, 
temperature, pressure or pain1. 
 
Figure 1 Structure of the skin. Adapted from1. 
The skin is composed of three layers: epidermis, dermis, and subcutaneous tissue (Figure 1). 
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2.1.1 Epidermis  
Epidermis is formed by keratinized stratified squamous epithelium and contains 
keratinocytes and three types of dendritic cells: melanocytes, Merkel cells, and Langerhans 
cells. Furthermore, there are four epidermal layers: stratum corneum, granulosum, spinosum 
and basale (Figure 2)1. 
 
Figure 2 Epidermal cells and the layers of epidermis. Adapted from1. 
Keratinocytes are the predominant cells of epidermis. Their main aim is to form keratin, a 
tough fibrous protein responsible for the protective barrier function of the skin. Keratinocytes 
are formed in the deepest layer of epidermis and are pushed towards the surface by the newly 
formed cells1. By the time they reach the skin surface, they are dead, completely flat and filled 
with keratin. This process is called keratinization4. 
The deepest epidermal layer is called the basal layer (stratum basale) or the germinating 
layer. It is firmly attached to the underlying dermis and formed by a single row of columnar cells 
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of stem origin. The layer also contains scarcely distributed Merkel cells responsible for the 
tactile sensation1. Melanocytes are dendritic cells derived from the neural crest and account 
for approximately 10 to 25% of cells of the basal layer4. One melanocyte together with 35–45 
keratinocytes form an epidermal melanin unit. To differentiate properly, melanocytes need 
contacts with the neighbouring keratinocytes and their growth factors, such as basic fibroblast 
growth factor (bFGF), hepatocyte growth factor (HGF), granulocyte-macrophage colony-
stimulating factor (GM-CSF), or interleukin-1α (IL-1α)5,6. Melanocytes mainly synthesize 
melanin, a dark pigment responsible for UV protection of the cell nuclei. It is synthesized in their 
special rounded organelles called melanosomes and transferred to the neighbouring 
keratinocytes1. Increased exposure to the ultraviolet light stimulates melanogenesis and 
melanosome transfer4. 
The spiny layer (stratum spinosum) is composed of several (usually five to twelve) layers 
of cells that do not divide as rapidly as the cells in the basal layer1,2. The spiny layer contains 
Langerhans cells, dendritic cells produced in the bone marrow migrating to the skin, where 
they participate in the response of the immune system2. 
The granular layer (stratum granulosum) is formed by three to five rows of prolonged and 
flattened keratinocytes. The cells contain multiple granules filled with keratin and glycolipids 
responsible for slowing down the water loss through epidermis1. The blood supply of epidermis 
comes from the dermis. Therefore, the more superficial layers are too far from the dermal 
capillaries to receive nutrients and cells undergo apoptosis1,2. 
The horny layer (stratum corneum) is the most superficial layer of the skin, containing 
multiple rows of flat, keratin-filled keratinocytes (approximately 25 to 30 layers). Both the keratin 
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and the increased thickness of the plasmatic membrane protects the skin against injuries. 
Furthermore, the layer is impermeable for water1. 
2.1.2 Dermis 
The dermis is responsible for providing nutrients and support to the epidermis2. It is 
composed of flexible connective tissue. It consists mainly of fibroblasts, macrophages, and 
mast cells. Blood cells (leukocytes, such as lymphocytes and plasmatic cells) enter dermis in 
response to various stimuli. Furthermore, it contains collagen, elastic, and reticular fibres 
synthesized by fibroblasts4. The dermis contains rich network of nerve fibres and blood 
vessels1. Their role is not only to provide nutrients and facilitate waste exchange, but 
thermoregulation as well4. 
There are two dermal layers, papillary and reticular layer. The papillary layer represents 
the superficial 20% of the dermis and is composed of a thin connective tissue. The deeper 
reticular layer accounts for the remaining 80% of the dermis. It consists of a dense connective 
tissue formed by a network composed of thick bundles of interconnected collagen and elastic 
fibres. The collagen fibres are responsible for strength and resilience of the skin, the elastic 
fibres enable the skin to stretch and contract1. Collagen accounts for approximately 70% of the 
dry weight of the dermis. Elastin forms finer fibres than collagen; elastin fibres are interwoven 
among the collagen fibres. With aging, collagen fibres lose their shape and elastin fibres lose 
their elasticity, leading to wrinkled appearance3. 
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2.1.3 Subcutaneous tissue 
The subcutaneous tissue consists mainly of adipose tissue. It anchors the skin to the 
underlying structures (i.e. muscles) so it can slide relatively freely. Given its poor conductive 
properties, it prevents heat loss1. 
2.2 Wound healing 
With the increasing incidence of obesity, type 2 diabetes and ageing population, wound 
healing represents a global medical issue, with its early and late complications being a frequent 
cause of mortality and morbidity7,8. Often, they are disguised as a comorbid condition and thus 
represent a hidden epidemic. Given these facts, the anticipated risks of non-healing wounds 
continue to increase dramatically. It poses a major threat to the public health and economy. 
Currently, annual costs of chronic wound care are projected to exceed 25 billion USD in the 
United States and represent approximately 2% of the total EU financial resources9,10. A proper 
understanding of the process of wound healing is thus essential11. 
Wounding and wound healing take part in every tissue and organ, many of the processes 
are common for all tissues8. Wound can be generally characterized as a disruption of skin 
continuity. The most common cause of major skin loss is thermal injury, followed by trauma and 
ulcerations secondary to diabetes, pressure and venous stasis12. In order to completely close 
the wound and restore the integrity of the organism, it requires a coordinated interaction of 
cells, soluble mediators and extracellular matrix within the immune system, blood coagulation 
cascade and inflammatory pathways13. Thus, it represents a complex biological process  in 
which many cell types (immune cells, endothelial cells, keratinocytes, and fibroblasts) undergo 
changes in their gene expression resulting in their proliferation, differentiation and 
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migration13,14. Disruption of the fine balance may result in failure of the wound to heal. Based 
on the healing timeframe, the wounds can be classified into acute and chronic wounds. For 
example, in the US, there were 35.2 million cases of significant skin loss in 1992 and out of 
these, 7 million of wounds become chronic12. In the Czech Republic, the prevalence of chronic 
wounds is approximately 1%, with a significant increase in the elderly population over 70 years 
of age (up to 4 to 5%)15.  
2.2.1 Acute wound healing 
Acute wounds are wounds that close in a timely and orderly manner (usually up to 8 to 12 
weeks), restoring both anatomical and functional integrity of the organism. For simplicity, acute 
wound healing is often artificially compartmentalized into four phases with considerable 
temporal overlap: the haemostasis, the inflammation, the proliferation and the remodelling7,14 
(Figure 3). 
Shortly following the injury, haemostasis occurs. The main aim of haemostasis is to stop 
the immediate bleeding, and the key players are platelets and fibrin16. The exposed collagen 
leads to platelet activation and aggregation, coagulation cascade activation and, finally, results 
in fibrin matrix (clot) formation. Fibrin mediates both haemostasis and homeostasis. It provides 
provisional matrix for several cell types (e.g. fibroblasts  or endothelial cells) and regulates their 
adhesion, proliferation and migration17,18. Furthermore, fibrin acts as a local reservoir of various 
growth factors and facilitates their spatiotemporal release in the area of wound19. Fibrin itself 
has pro-angiogenic properties. Not only it provides a supportive matrix, it also acts as a 
chemoattractant for endothelial cells in to the clot. The invading cell then replace fibrin with the 




Figure 3 Phases of wound healing. Wound healing consists of four overlapping phases. PMN – polymorphonuclear 
neutrophil. Adapted from16. 
Blood clotting induces platelet degranulation and numerous cytokines and growth factors 
(e.g. platelet-derived growth factor (PDGF), insulin-like growth factor-1 (IGF-1), epidermal 
growth factor (EGF) and transforming growth factor-beta (TGF-β)) are released from the 
platelet alpha granules20. Thus, the released bioactive molecules initiate inflammatory cells 
chemotaxis and tissue repair14. 
The main aim of the inflammatory phase is to establish an immune barrier against 
microbial invasion. The inflammatory cells (polymorphonuclear neutrophils, macrophages) 
provide antimicrobial defence via phagocytosis and reactive oxygen species (ROS) and 
removal of the devitalized tissue due to the released proteases (elastase, collagenase and 
other proteases from the family of matrix metalloproteinases (MMPs))14,21. MMPs are involved 
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in the ECM degradation, cell migration and tissue remodelling; their elevated levels were 
associated with chronic wounds failing to close22,23. 
By secreting growth factors and cytokines, the inflammatory cells induce the formation of 
granulation tissue. Reestablishment of the normal blood flow leads to epidermal and dermal 
cell migration and proliferation, and as the number of inflammatory cells in the wound bed 
begins to decrease, usually few days following the initial wounding, the proliferative 
processes start to prevail14. The mechanism of resolution of the inflammatory phase is 
currently not fully understood. However, key players in the transition from inflammation to 
proliferation are believed to be macrophages. The phagocytic pro-inflammatory M1 subset of 
macrophages is transformed into the M2 macrophages, supporting the reparative processes 
and proliferation and inducing angiogenesis24. The synthesis of necessary growth factors is 
taken over by fibroblasts, keratinocytes and endothelial cells, maintaining proliferation and 
migration of the cells14. To support the reparation processes, an adequate blood supply and 
nutrient/gas exchange is required. 
Thus, a robust angiogenesis and vasculogenesis must be initiated and sustained. The 
hypoxic environment of the wound fosters the production of proangiogenic molecules (vascular 
endothelial growth factor (VEGF), bFGF and PDGF)14. In response to the bioactive molecules, 
endothelial cells migrate towards the wound upon degradation of the basal membrane, 
proliferate and eventually form new blood vessels25. 
Normal blood supply fosters a suitable microenvironment for epidermal and dermal cell 
migration and proliferation, which leads to re-epithelialization and restoration of the integrity of 
the organism. Fibroblasts synthesize extracellular matrix, forming granulation tissue. The 
provisional, highly hydrated matrix consisting mainly of type III collagen, fibrin, fibronectin and 
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hyaluronic acid, is gradually changed into denser extracellular matrix synthesized by 
fibroblasts, containing mainly collagen I25,26. The collagen synthesis and degradation reach an 
equilibrium approximately three weeks after the injury and then, the rate of collagen synthesis 
gradually slows down16. The collagen crosslinking and reorganisation of the ECM occur within 
the remodelling phase for several weeks, leading to the formation of a relatively acellular scar 
with tensile properties reaching up to 80% of the tensile properties of the unwounded skin7,26. 
2.2.2 Chronic wound healing 
Chronic wounds are defined as wounds failing to proceed with the timely and orderly 
manner of wound healing and persisting for more than three months following the initial 
injury27,28. Based on aetiology, they can be classified into vascular (due to venous hypertension 
and/or arterial insufficiency), diabetic and pressure ulcers14. They do not follow the precise 
cascade of processes, usually being halted in the inflammation phase, preventing the 
progression into the reparative synthetic phase20. Typically, they result as a complication of 
other underlying conditions, such as diabetes or other neuropathies, or local tissue hypoxia and 
heavy bacterial burden, or simply due to ageing9,14,20. The growing body of evidence is 
advancing our understanding of the background mechanisms of chronic wounds. So far, the 
identified factors impairing healing include: reduction in the bioavailability of the growth factors 
and receptors due to excessive proteolytic activity in the wound bed and lack of their inhibitors, 
abnormal production of matrix proteins, decreased proliferative potential of the residing cells, 
insufficient blood perfusion, persistent infection and formation of a drug-resistant biofilm14. Such 
diverse aetiology hinders the search for a single effective therapeutic agent20. 
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2.2.3 Growth factors, cytokines and chemokines significant in wound healing 
As was mentioned above, growth factors play an important role in the process of wound 
healing. To the best-characterized growth factors belong the growth factors of epidermal growth 
factor family, including among others epidermal growth factor and transforming growth factor-
alpha, acting through an EGF receptor (a tyrosine kinase transmembrane protein)29. Activation 
of the EGFR stimulates keratinocyte proliferation and migration and thus represents a key factor 
in the process of reepithelization30. The epidermal growth factor is produced by multiple cells, 
including platelets, macrophages, and fibroblasts. In a paracrine fashion, it stimulates 
keratinocytes. It has been shown, that EGF is upregulated in acute wounds29. There are studies 
in chronic wounds showing EGFR localized in the cytoplasm of keratinocytes, instead of their 
membrane, suggesting down-regulation of the receptor, its mis-localization and subsequent 
inhibition of epithelialization31. Further studies describe degradation of EGF in the proteolytic 
environment of a chronic wound, in comparison to acute wounds32. Transforming growth 
factor-alpha (TGF-α) has similar effects to EGF, however, it has been found that its absence 
does not hinder wound healing33. Its role is in early stages of re-epithelialization. The effect of 
TGF-α is concentration- and duration-dependent. At low levels, it promotes healing by 
supporting production of growth factors by macrophages and stimulating inflammation. 
However, at high levels, particularly over prolonged periods of time, it prevents synthesis of 
ECM proteins and tissue inhibitors of metalloproteinases (TIMPs) and promotes synthesis of 
MMPs, and thus contributes to the inability of the wound to close29. 
Another important growth factor family is the fibroblast growth factor family (FGFs). The 
FGFs are synthesized by keratinocytes, fibroblasts, endothelial cells, smooth muscle cells, and 
mast cells29. They bind to a FGF receptor that needs proteoglycans (such as heparin) for 
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activation34. FGF-1 and FGF-2 (acidic or basic fibroblast factor, respectively) play a role in 
granulation tissue formation, reepithelialization, and tissue remodelling35. It regulates synthesis 
of components of the ECM, keratinocyte and fibroblasts migration and production of 
collagenases29. In contrast to acute wounds, the FGF-2 levels are decreased in chronic 
wounds36. Furthermore, keratinocyte growth factor-1 and -2 (KGF-1 and KGF-2, or FGF-7 
and FGF-10, respectively) act in a paracrine fashion on keratinocytes and stimulate their 
proliferation and migration. In addition to that, they stimulate transcription of factors involved in 
ROS detoxification, preventing the ROS-induced apoptosis of keratinocytes37. FGF-7 is also a 
potent mitogen of vascular endothelial cells and plays an important role during later stages of 
neovascularization38. 
Transforming growth factor-beta1-3 (TGF β1-3) are proteins significant in wound 
healing. They are produced by fibroblasts, keratinocytes, platelets and macrophages29. 
Following an injury, expression of TGF-β1 increases. In the inflammation phase, it stimulates 
recruitment of immune cells and tissue debridement, however, in sterilized wounds it 
deactivates superoxide production in macrophages in vitro and thus plays role in protection of 
the surrounding healthy tissue and helps to prepare the wound for formation of granulation 
tissue39–41. It strongly stimulates collagen type I and III production. To inhibit the break-down of 
the newly-formed collagen, it decreases the production of metalloproteinases MMP-1, -3, and 
-9 and promotes synthesis of TIMP-129. 
The members of platelet derived growth factor (PDGF) family are produced by platelets, 
macrophages, endothelial cells, fibroblast, and keratinocytes, and include 5 isoforms PDGF-
AA, -AB, -BB, -CC, and –DD29. PDGF affects every stage of wound healing and belong to the 
first factors released in response to wounding. Shortly after injury, PDGF is released from 
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platelets and attracts immune cells and fibroblasts and stimulates their proliferation42. 
Furthermore, it promotes synthesis of other growth factors, such as TGF-β in macrophages 
and VEGF in endothelial cells43,44. During epithelialization, it stimulates production of IGF-1 
(IGF-1 increases keratinocyte mobility) and thrombospondin-1 (TSP-1). TSP-1 postpones 
proteolytic degradation at the site of the wound and promotes proliferation45,46. Additionally, it 
induces the transformation of fibroblasts into myofibroblasts, and by affecting the levels of 
MMPs, it helps to break down the old collagen during remodelling47. 
Vascular endothelial growth factor (VEGF) is essential for proper angiogenesis. It is 
significantly upregulated in hypoxic environment, given its constitutional synthesis in the skin is 
almost negligible. During its early stages, it promotes endothelial cell migration and 
proliferation. The hypoxia in the wound stimulates VEGF release leading to angiogenesis, and, 
thus, the tissue perfusion is restored, and the oxygen tension increased. The expression of 
VEGF is further stimulated by other growth factors in a paracrine manner (e.g. TGF-β1, EGF, 
bFGF, and PDGF-BB)35. 
During the inflammatory phase of wound healing, pro-inflammatory cytokines such as 
interleukin-1 (IL-1), interleukin-6 (IL-6) or TNF-α play role. IL-1 is produced by immune cells 
(neutrophils, macrophages, and monocytes) and keratinocytes. It increases keratinocyte 
migration and proliferation and activates fibroblasts. Similarly, IL-6 is secreted by neutrophils 
and monocytes. It stimulates keratinocyte proliferation and in a autocrine manner, it further 
attracts neutrophils to the site of injury29. The inflammatory phase of wound healing is also 
governed by chemokines that attract various cell types to the site of injury. The presence of 
chemokine receptors on the cells residing in the wounded tissue suggests contribution of 
chemokines during angiogenesis, re-epithelialization, and remodelling as well37. 
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2.2.4 Management of chronic wounds 
Over the past decades, our understanding of the cellular and molecular mechanisms 
underlying wound healing has advanced greatly12. Based on the current knowledge of the 
problematics of wound healing, chronic wounds (regardless of their aetiology) are treated using 
a multistep approach. Firstly, the necrotic tissue must be removed using surgical tools or 
debriding agents (typically enzymatic, papain-based and collagenase-based preparations)14. 
The debridement of the necrotic tissue or any foreign material increases the chances of the 
wound to close and the presence of necrotic or foreign material further increases the risk of 
infection and prolongs the inflammatory phase48. Following wound debridement, it is necessary 
to minimize the present inflammation and infection using antibiotics, topical antiseptics, and 
anti-inflammatory agents. Furthermore, the injured tissue needs to be cover with a proper 
dressing. The dressings may be classified based on their function (i.e. debridement, 
antibacterial, occlusive or absorbent), type of the used material (biological, biosynthetic or 
synthetic), or the physical form of the dressing (ointment, film, foam, or gel)48–50. Moist dressings 
help to promote the inflammatory phase and accelerate the wound closure, on the other hand, 
traditional dry gauze dressings may degrade the process and disrupt the newly formed 
epithelium when removed. The golden standard of modern wound dressings is represented by 
a low-adherent dressing, such as hydrocolloids and hydrogels (material that absorbs the wound 
exudate while keeping the wound moist), alginate dressings or non-woven fibrous dressings 
with a high absorption capacity51. The traumatic removal of the dressing during dressing 
exchanged can be minimized using foam dressings made of collagen52. 
The therapy of large skin defects includes skin grafting as the wound dressings (whether 
traditional or modern) cannot make up for the lost tissue, especially in case of severe burns48. 
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A skin autograft contains the patient’s own full epidermis and a portion of dermis. This approach 
is called the split-thickness autologous skin grafting. However, there may be shortage of the 
donor skin for transplantation and, depending on the thickness of the transplanted dermis, the 
approach may lead to excessive scarring53. Full-thickness skin grafting (full epidermis and full 
dermis transplanted) is known to not be associated with so much scarring, but only defects 
<2% of the total body surface area can be treated using full-thickness grafting54. Skin allograft 
may address the donor site shortage, however, there is a risk of rejection of the transplanted 
tissue12. 
The increasing knowledge on molecular and biologic processes of wound healing led in the 
past decades to innovation of the wound care and development of techniques and dressings 
that facilitated more rapid closure of the wounds, more aesthetic scars and decreased incidence 
of keloid formation. Using the engineered dressings, proper moisture in the wound is 
established, and, finally, epithelialization and granulation tissue formation is promoted by 
specific therapies (e.g. delivery of growth factors)14. 
Generally, the levels of growth factors are decreased in chronic wounds, due to their 
susceptibility to the proteolytic environment29. Therefore, multiple clinical trials have been 
performed, evaluating the delivery of exogenous growth factors necessary for fostering the 
process of wound healing. However, given the promising in vitro results and the resulting 
expectations, the outcomes seemed to be rather inconclusive and not clearly convincing35. 
Topically administered EGF failed to significantly promote healing in the setting of a chronic 
venous ulcer55. Similarly, multiple clinical trials for chronic wound healing were failed by TGF-
β29, FGF or VEGF35. Up to date, the only growth factor approved by the Food and Drug 
Administration (FDA) in chronic wound healing is PDGF-BB. Efficacy of its topical 
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administration in pressure ulcers was investigated, showing significant acceleration of 
healing56,57, and similarly promising results have been obtained in diabetic ulcers58, leading to 
the FDA approval. Among the reasons why the topical administration of recombinant human 
growth factors did not yield better outcomes are the complex signalling of the individual growth 
factors and their concentration-dependent effects, maybe requiring combinations of the growth 
factors, and their insufficient retention at the site of the wound. Thus, novel strategies for 
delivering the bioactive molecules are desperately needed35. 
2.3 Skin tissue engineering 
Tissue engineering, an interdisciplinary field, in general aims to restore the integrity and 
function of a damaged tissue or an organ in the condition of end-stage failure using cells and/or 
extracellular matrix. The exploration of the idea of seeding viable cells on an appropriately 
designed scaffold began in 1970s. The keratinocyte culture was established in 1975, resulting 
in transferring of sheets of keratinocytes to burn victims or using collagen-based matrix to 
promote the growth of fibroblasts59,60. These experiments were followed by development of 
novel scaffolds composed of synthetic, biodegradable polymer materials that would allow 
tailoring of chemical and physical properties to the designed purpose of the scaffolding 
systems61. 
Nowadays, there are two main strategies to fulfil this aim. Firstly, scaffolds can be used 
simply as a supporting material for cells that are expanded in vitro. The cells then synthesize 
extracellular matrix, a foundation of the newly formed tissue for transplantation. Following the 
transplantation, proportionally to the new ECM synthesis, the scaffold is gradually degraded. 
This represents the main idea of tissue engineering in the narrow sense of the word. The 
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second approach, in the narrow sense of the word called the regenerative medicine, uses the 
scaffold as a drug or bioactive molecule delivery system, inducing cell recruitment, their 
migration, adhesion, proliferation and/or differentiation into the preferred type upon the 
transplantation of the scaffold into the body (Figure 4)12. 
 
Figure 4 Summary of principles of skin tissue engineering and regenerative medicine. Adapted from12. 
However, the above-mentioned strategies do not exclude themselves and it is possible to 
easily combine them together62. Whether the scaffolding systems contain cells or not, they are 
usually fabricated using polymers (synthetic or natural), and functionalized with bioactive 
molecules to stimulate the cells to migrate, proliferate, and differentiate63. An ideal skin 
substitute be sterile, biodegradable, non-toxic, non-inflammatory and non-immunogenic, it 
should act as a barrier against microbial contamination and adhere to the wound rapidly. 
Furthermore, it should be easy to handle and cost-effective. The available skin substitutes may 
be categorized based on the anatomical structure as epidermal, dermal, or epidermal-dermal 
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or based on their composition as acellular and cellular, based on the biomaterial used as 
biologic (autologous, allogeneic or xenogeneic) or synthetic53. 
2.3.1 Acellular skin substitutes 
The acellular skin substitutes represent the most basic type of the substitutes, acting 
primarily as a barrier to fluid loss and microbial contamination64. They serve as a temporary 
cover and are removed when the wound is healed or when an autograft is available. Usually, 
they are used in mid-dermal partial thickness wounds53. These products contain Biobrane®, 
Alloderm®, and Integra®. The Biobrane® is a two-component epidermo-dermal substitute, 
composed of a very thin nylon membrane serving as a dermal analogue and a very thin silicon 
membrane servings as an epidermal analogue. Both components are covered with porcine type 
I collagen peptides. The Integra® is a bilayer consisting of a silicon epidermal analogue and 
dermal analogue composed of porous bovine collagen and shark chondroitin-6-sulphate 
glycosaminoglycan. Upon wound revascularization, the silicone layer is removed and replaced 
by a thin split-thickness skin graft53,65. The Alloderm® is a human decellularized lyophilized 
dermis with no epidermal layer, providing matrix for the infiltrating fibroblasts. The 
disadvantages of the above-mentioned skin substitutes include accumulation of the 
exudate64,65. 
2.3.2 Cellular skin substitutes 
Cellular skin substitutes consist of a matrix or a mesh in combination with expanded 
fibroblasts and/or keratinocytes, depending whether the skin substitute is epidermal, dermal, or 
composite. The cellular skin substitutes may be allogeneic or autologous. 
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The autologous epidermal substitutes include Epicel®, Bioseed® and Laserskin®. The 
Epicel® is an FDA-approved permanent skin substitute composed of sheets of patient’s 
keratinocytes expanded from skin punch biopsies delivered on a petrolatum gauze support53. 
The keratinocytes may be further delivered using other scaffolding systems, such as 
hyaluronan membrane (Laserskin®) or fibrin sealant (Bioseed®)48. An example of an autologous 
dermal substitutes is Hyalograft3D. The autologous cultured fibroblasts are seeded on a 3D 
hyaluronic acid-derived meshes66. The TissueTech autograft system is a combination of an 
epidermal substitute (Laserskin®) and a dermal substitute (Hyalograft3D). The epidermal 
substitute is applied 7 days after the dermal substitutes. The efficacy of the system was 
evaluated in patients with non-healing ulcers of various aetiology with promising outcomes67. 
The allogeneic dermal substitutes include Dermagraft® and Transcyte®. The Dermgraft® is 
composed of a biodegradable polyglycolic acid (PGA) mesh seeded with neonatal foreskin 
fibroblasts. The PGA mesh is resorbed within three to four weeks65. The Transcyte® is a bilayer 
product, composed of a silicone membrane and a nylon/collagen mesh seeded with neonatal 
foreskin fibroblasts. The silicone membrane protects the wound and allows its visual 
inspection66. Both products are cryopreserved. The freezing process destroys the cells, 
reducing the risk of an immune reaction while maintaining the synthesized ECM and growth 
factors. These constructs provide a dermal matrix that facilitates re-epithelialization of the 
wound by the patient’s keratinocytes. An example of an allogeneic composite substitute is 
Apligraf®. It was approved by the FDA in 1998 and it was the first composite skin graft used in 
the indication of venous and neuropathic leg ulcers64. It contains both neonatal foreskin 
allogeneic fibroblasts and keratinocytes delivered in a bovine collagen gel. Firstly, the 
fibroblasts are seeded in the collagen gel and within 14 days, the fibroblasts synthesize a new, 
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dense collagen matrix. After the two weeks, the construct is seeded with keratinocytes and the 
cells proliferate for 4 days. Following cell expansion, the substitute is lifted to the liquid/air 
interface and the keratinocytes differentiate and form a stratum corneum. Then, the skin 
substitute is ready to use65. The Apligraf® construct was successfully used in non-healing 
venous ulcers, diabetic ulcers and pressure ulcers68. 
However, the acellular constructs represent a more promising solution to the issues 
associated with wound healing. They are less complex to fabricate, more cost-effective, user-
friendly and minimize the risk of transmission of infectious agents. The material of the construct 
should be conductive and should recruit cells of the host tissue. The dressings are usually made 
of synthetic or natural biopolymers; however, the only marketed products are made of natural 
biopolymers (i.e. collagen, fibrin, and/or hyaluronan). Engineered drug delivery vehicles are 
needed to improve the outcomes and electrospun fibrous mats may represent a viable 
solution69. 
2.4 Nanofibrous scaffolds 
Nanofibres are fibres with diameter in the nanometre range. Their unique properties 
predetermine them for tissue engineering applications. The properties include70: 
• high volume-to-surface ratio, allowing easy and tailorable functionalization with 
bioactive molecules; 
• controlled porous structure with high pore interconnection, allowing nutrient and 
waste exchange; 
• microarchitecture in the nanoscale range, resembling the topography of native ECM, 
and thus promoting cell adhesion, proliferation, and differentiation. 
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These features significantly distinguish nanofibers from the conventional woven textiles, as 
their diameters are in the micrometre scale and their surface-to-volume ratio is lower71. 
However, nanofibres may not only mimic the structure of ECM but its function as well. 
Generally, cells respond to three types of stimuli contained in the ECM; to its topography and 
microarchitecture, physical properties (elastic modulus and other mechanical properties, such 
as resilience or strength), and finally to biochemical stimuli (such as the charge, 
hydrophobicity/hydrophilicity, sequence of amino acids or functional groups)72. Therefore, 
functionalization of nanofibres with bioactive molecules, such as growth factors, adhesive 
molecules, differentiation factors or drugs, may help to induce the desired effect. 
Various nontoxic, biodegradable and biocompatible synthetic and natural polymers may be 
spun into nano- and/or microfibres. Biologic polymers (proteins such as collagen, gelatine, or 
fibrinogen, or polysaccharides such as cellulose, chitin or chitosan) provide their own intrinsic 
bioactive properties, allowing them to enhance the cellular response of the prepared system73. 
However, the adjustment of their mechanical or degradation properties is not optimal. In 
contrast, it is usually possible to tailor the mechanical properties of the synthetic polymers to 
the specific application (such as porosity, degradation time or mechanical properties) and they 
allow uniform, large-scale production and prolonged shelf-time in comparison to the natural 
polymers73,74. Several synthetic polymers were used to develop synthetic polymer scaffolds for 
skin tissue engineering, including poly-ε-caprolactone (PCL), poly-L-lactic acid (PLLA) or 
polyglycolic acid (PGA). PCL is an FDA-approved biocompatible, biodegradable synthetic 
polymer; its degradation products do not induce local pH decrease. The degradation rate is 




It was shown the cell recognition of the synthetic scaffolds may be somewhat limited. 
Therefore, to combine the advantages of both the synthetic and natural polymers, novel blend 
materials have been developed76. These materials included for example chitosan/PCL77, 
collagen/PCL78,79 and collagen/polylactic-co-glycolic acid (PLGA)80 blends for skin tissue 
engineering, furthermore, gelatine has been shown to improve wound healing outcomes when 
combined with PCL81. 
The most common techniques of nanofibre fabrication include the electrospinning, 
centrifugal spinning, phase separation, and self-assembly. The latter two techniques are 
laboratory techniques and the likelihood of their prospective commercialization is rather low. 
Furthermore, only a limited number of polymers may be used for fibre fabrication using these 
techniques which will be described only briefly. The phase separation and a subsequent 
production of nanofibres from a homogenous polymer solution is induced by its rapid cooling. 
During the cooling, gelation of the solution occurs, with an internal network of nanofibers. 
Finally, the solvent is removed. The self-assembly technique uses small molecules such as 
peptides or nucleic acids bound with noncovalent interactions to form nanofibres82. 
2.4.1 Electrospinning 
Electrospinning is the most commonly used technique to produce nanofibres, resulting in 
continuous, long fibres with a diameter ranging from 3 nm to 10 µm82. The method may be used 
to spin almost any polymer (conductive and nonconductive) and enables encapsulation of 
various bioactive compounds83,84 as well. During electrospinning, fibres are formed using an 
electrostatic force generated by a high voltage. The high voltage applied to the polymer solution 
induces migration of free electrons, and thus, a charge is formed at the surface of the polymer 
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and, consequently, an electric field is established between the surface of the polymer and a 
collector (charged or grounded). When increasing the voltage applied, and thus the intensity of 
the formed electric field, the surface tension of the polymer solution is overcome, and polymer 
jets are formed. On the way to the collector, the fibres elongate and become thinner. Finally, 
dried nanofibres are deposited on the collector in a random manner85. 
The common laboratory setup (also known as the capillary electrospinning) consists of a 
source of high voltage, syringe with a needle and a collector. However, the yield of such setup 
is low (only one polymer jet is formed) and the obtained layer is not homogenous. Therefore, 
for commercial purposes, a method using self-formation of the polymer jets on a free liquid 
surface was developed by Elmarco (the Nanospider™ technology). The principles underlying 
the electrospinning from a free liquid surface were described by86. 
The process of electrospinning may be affected by various variables: characteristics of the 
polymer solution, parameters of the electrospinning itself and parameters of the environment. 
The characteristics of the polymer solution include mainly the viscosity of the solution, 
surface tension and conductivity of the solution. The polymer viscosity is closely linked to the 
polymer concentration and its molecular weight. Increasing both the parameters leads to 
increase in polymer chain entanglement and thus its viscosity. If the viscosity of the solution is 
low, micro- and nanoparticles are formed during the process called electrospraying. With 
increasing viscosity, firstly, beaded fibres are formed (fibres containing spherical defects), 
followed by smooth fibres with further increase in the solution viscosity. The diameter of the 
fibres further increases with the increasing viscosity. However, too high viscosity of the solution 
prevents the electrospinning process from occurring. The beaded defects may also occur if the 
surface tension of the polymer solution is too high. To lower the surface tension, solutions such 
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as ethanol or surfactants are added to the solvent. Furthermore, increase in the conductivity of 
the solution leads to decrease in the diameter of the formed fibres. The conductivity may be 
increased by addition of mineral salts or bioactive molecules87. 
The parameters of the process include the applied voltage, polymer flow rate, the needle 
orifice, collector-electrode distance and the morphology of the collector itself. The 
electrospinning process may also be influenced by the relative humidity or temperature88. 
2.4.2 Centrifugal spinning 
Centrifugal spinning is an alternative technology of ultrafine fibre fabrication that does not 
require the high voltage. Instead of the electrostatic forces, the technology uses centrifugal 
forces to produce fibres from melts or solutions89. The polymer solution/melt is placed in a 
rotating spinning head, giving rise to formation of centrifugal forces. Similarly, as in case of 
electrospinning, when the centrifugal forces overcome the surface tension of the polymer (i.e. 
the rotary speed reaches a critical value), a polymer jet is ejected from a nozzle of the spinning 
head. The fibres undergo stretching and elongation and are eventually deposited on a 
collector90. The mean diameter of the centrifugal spun fibres is higher (in the range of hundreds 
of nanometres to tens of micrometres)91 in comparison to the diameters obtained via 
electrospinning, with higher variance due to the less controlled fabrication procedure92. The 
centrifugal spun fibres form rather 3D-like fluffy layers with higher porosity, improving the cell 
penetration that is somewhat hampered in case of the 2D-like electrospun layers91. The Figure 
5 illustrates the basic principles and differences in electrostatic (Figure 5A) and centrifugal 




Figure 5 Schematic illustration of the fibre forming techniques. A – Scheme of electrostatic spinning illustrates the 
deposition of polymer fibres formed on a wire electrode and deposited onto a charged collector due to high voltage applied to 
the wire electrode. B – Scheme of centrifugal spinning illustrates polymer fibres deposited under vacuum from a rotating 
emitter (Lukasova et al., submitted manuscript). 
2.4.3 Functionalization of the fibrous scaffolds with bioactive molecules 
To induce the desired cellular response, nanofibres may be functionalized with various 
bioactive molecules. The half-time of the bioactive molecules is rather low, therefore, various 
drug delivery systems have been developed to protect the susceptible molecules from the 
environment and to maintain their sustained release. The process of functionalization may 
occur during their preparation, leading to blend, coaxial, or emulsion fibres, or by simple 
adsorption of the bioactive molecules to the surface of the already fabricated nanofibres (Figure 
6)83. 
The surface adsorption of the bioactive molecules represents a viable post-spinning 
modification of the nanofibres (Figure 6A). It enables to deliver different bioactive molecules 
from the same scaffold and, furthermore, the drug is not exposed to any risks arising from the 
fabrication process (i.e. the high voltage in electrospinning or solvents). The disadvantage of 
such system is the relatively rapid burst released of the adsorbed molecules93. For example, 
antibiotics were adsorbed to poly-ε-caprolactone electrospun nanofibers. A significant decrease 
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in post-operative abdominal adhesions was observed in rat model in the antibiotics-loaded 
nanofibres when compared to the plain nanofibres94. Furthermore, the release may be 
prolonged by a covalent coupling of the drug to the polymer matrix of the scaffold. EGF was 
chemically immobilized to the surface of PCL/polyethylene glycol (PEG) nanofibres and its 
effect on wound healing was evaluated in primary keratinocyte culture and in vivo in dorsal 
wound in diabetic mice. The immobilized EGF showed superior healing properties in 
comparison to the plain PCL and EGF solutions adsorbed to the PCL nanofibres without any 
chemical modification95. 
 
Figure 6 Nanofibre functionalization with bioactive molecules. The scheme shows post-spinning adsorption of the 
bioactive molecules to the surface of the nanofibres (A) and functionalization of the nanofibrous mats during their fabrication: 
blend electrospinning (B), coaxial electrospinning (C), and emulsion electrospinning (D). Adapted from69. 
Other options include addition of the bioactive molecule to the polymer solution prior to the 
fabrication of the nanofibres. The release characteristics of the bioactive molecule may be 
adjusted through the spinning properties. The simplest technique is the blend spinning (Figure 
6B). The bioactive molecules are simply added to the polymer solution and are later 
incorporated in the polymer matrix96. However, during the spinning process, the bioactive 
molecules are in contact with the harsh organic solvents and together with the high voltage in 
case of electrospinning, it may result in changes of the protein conformation or its biological 
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activity97. Furthermore, it was shown that blend electrospinning of a horseradish peroxidase 
enclosed in liposomes led to their disintegration and release of the enzyme outside of the 
nanofibres. On the contrary, coaxial electrospinning of the horseradish peroxidase-containing 
liposomes resulted in increase of the encapsulation efficiency and maintained the bioactivity of 
the enzyme84. 
Therefore, coaxial spinning may be used to protect the susceptible molecules (Figure 
6C). Two separate channels for two separate solutions (polymer with an organic solvent and 
an aqueous phase containing the bioactive molecules) are used, giving rise to nanofibres of a 
core/shell nature97. The process of spinning is so fast the solutions do not mix. Furthermore, 
by adjusting the core and/or shell polymer characteristics, the release kinetics of the 
encapsulated molecules may be adjusted98. 
The needle-in-needle setup of the coaxial electrospinning requires special adjustments to 
the electrode to be made. Therefore, core/shell nanofibres can be fabricated by the emulsion 
spinning technique without the need to adjust the spinning device (Figure 6D). The emulsion 
is formed by two immiscible fluids (usually a polar and a nonpolar in nature); a surfactant may 
be added to stabilize the solution. Usually, the aqueous solution containing the bioactive 
molecules is dispersed in the organic polymer solution. Depending on the amount of the 
aqueous droplets, they may be interconnected into a continuous core in the core/shell 
nanofibers91. 
2.5 Platelet-derived bioactive molecules 
The process of tissue healing is regulated by a number of cytokines, growth factors and 
other bioactive molecules, as was described above. The important growth factors include e.g. 
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VEGF that triggers angiogenesis or PDGF-BB that induces mesenchymal stem cell recruitment 
to the site of injury. Although the knowledge on the mechanisms and role of the growth factors 
has advanced greatly, the clinical transfer of synthetic growth factors has been somewhat 
limited. Some clinical efficacy was shown in clinical trials of PDGF-BB, bone morphogenetic 
protein-2 (BMP-2), and bone morphogenetic protein-7 (BMP-7)99, however, there are concerns 
regarding its safety100,101 and cost-effectiveness102. Furthermore, trying to mimic the complex 
wound healing cascade using single growth factors would be oversimplified and inefficient103. 
Therefore, platelet-derived bioactive molecules could represent a suitable solution. The 
rationale for the use of platelet derivatives to promote tissue healing is in their high content of 
native growth factors and cytokines in physiological ratios104. Their translation is further driven 
by their availability, relative cost-effectiveness105, autologous nature and applications ranging 
from dermatology, to orthopaedics and ophthalmology103. 
2.5.1 Platelets 
Platelets are multifunctional anucleated cells. Their key role is in haemostasis; however, 
they also participate in the wound healing cascade. Platelets are shed from the cytoplasm of 
megakaryocytes in the bone marrow, then they enter the blood circulation. They are of discoid 
shape and approximately 2.0–4.0 µm in size106. In blood, their normal concentration is 
150,000–450,000 cells/µL. On average, platelets remain in the circulation for 8 to 10 days; after 
then, they are sequestered by the spleen and liver107. Thanks to their shape and size, they 
constantly monitor the integrity of the vascular wall. If the endothelial integrity is disrupted and 
subendothelial components (such as collagen, fibronectin or von Willebrand factor) are 
exposed, adhesion and activation of platelets occurs, followed by their secretion106. 
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Briefly, platelets are anchored to the exposed collagen and von Willebrand factor via the 
glycoprotein GP IIb/IIIa and GPIa/IIa, respectively, followed by further potentiation of the 
reaction by the platelet-platelet interaction. Platelets are activated and undergo morphological 
changes, resulting in a spiny sphere with multiple pseudopod extensions106. Finally, platelets 
release the bioactive molecules contained in their granules. The bioactive molecules contain 
pro-inflammatory cytokines and chemokines attracting immune cells and stimulatory/inhibitory 
mediators of cell migration and/or proliferation; the wound healing cascade is initiated108. 
Within platelets, the bioactive molecules are stored in three types of granules: alpha-
granules, dense granules, and lysosomes. The alpha-granules (200 to 500 nm) are the most 
abundant type of granules; there are approximately 50 to 80 granules per platelet, comprising 
10% of the platelet volume. There are much fewer dense granules (150 nm), approximately 3 
to 6 per one platelet. Finally, the lysosomes are approximately 150 to 300 nm in size109. The 




Table 1 Examples of bioactive molecules contained in platelets. Adapted from108,110. RANTES = Chemokine 
Regulated on Activation, Normal T Cell Expressed and Secreted; MCP-1,-3 = Monocyte chemoattractant protein-1,-3; MIP-1 
= Macrophage inflammatory protein-1; VEGF-1,-C = Vascular endothelial growth factor-1,-C; IGF-1, -2 = Insulin-like growth 
factor -1,-2; FGF = Fibroblast growth factor; PDGF-AA,-AB,-BB = Platelet-derived growth factor-AA,-AB,-BB; EGF = 
Epidermal growth factor; TGF-β = Transforming growth factor-β; ADP = Adenosine diphosphate; ATP = Adenosine 
triphosphate. 
2.5.2 Platelet derivatives 
Platelet concentrates represent essential therapeutic agents in transfusion medicine. The 
platelet concentrates are routinely used as a haemostatic tool in case of thrombocytopenia or 
platelet dysfunction. Generally, the shelf-life of the collected platelet in transfusion products is 
5 days107. After 5 days, the risk of transmission of a disease is too high and the platelets lose 
Granules Bioactive molecule Function 
Alpha-granules   




Inactivation of plasmin 
Chemokines RANTES, MCP-1, MCP-3, 
MIP-1α 
Chemotaxis, inflammation modulation 
Adhesion Molecules P-Selectin 
Vitronectin 
Fibrinogen 
Binding and recruitment of leucocytes 
Cell adhesion, chemotaxis 
Fibrin clot formation 
Growth factors VEGF-A, VEGF-C 
IGF-1, -2 
FGF 





Cell proliferation, maturation 
Angiogenesis, fibroblast proliferation 
Chemoattraction, cell proliferation 
Inhibition of angiogenesis 
Cell proliferation 
Stimulation of matrix synthesis 
Dense granules ADP, ATP, Serotonin, Ca++, 
Epinephrine, Histamine 
Platelet activation, haemostasis 
Lysosomes Elastase, collagenase, 
cathepsin 
Degradation of ECM, remodelling 
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their haemostatic activity and are considered outdated. There is an overall shortage of the 
platelet products and yet, even in developed countries, approximately 10 to 20% of the 
produced platelet concentrates are discarded111. Despite the rather rapid loss of their 
haemostatic function, platelets have been shown to maintain their proliferative potential for up 
to 21 days112. The regenerative potential of platelet derivatives was described more than 40 
years ago, when the positive influence of addition of platelets to platelet-poor plasma on 
stimulation of monkey arterial smooth muscle cells proliferation was described113. Since then, 
various platelet derivatives have been prepared and tested. 
Blood consists of various cellular, sub-cellular, and molecular components crucial for the 
wound healing process and tissue regeneration. In general, it is composed of plasma 
(containing adhesive proteins such as albumin, fibrinogen or clotting factors, together with 
electrolytes and growth factors) and red blood cells, white blood cells, and platelets. Blood 
separation results in the production of various blood derivatives, see Figure 7114. 
 
Figure 7 Summarized production of various blood derivatives. Adapted from114. 
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The obtained products differ in their content, i.e. in the concentrations of fibrin, leucocytes, 
and growth factors114. Generally, blood derivatives may be classified according to their 
leucocyte content, fibrinogen/fibrin content and platelet content. The varying composition of the 
product affects its behaviour. For example, it has been shown that both the leucocyte-rich 
platelet-rich plasma (PRP) and leucocyte-poor PRP stimulate proliferation of tendon 
stem/progenitor cells and induce their differentiation into tenocytes, however, the leucocyte-
rich PRP induced mainly catabolic, inflammatory changes in the tenocytes, in contrast to the 
mainly anabolic changes induced by the leucocyte-poor PRP115. Similarly, the platelet 
derivatives rich in fibrinogen/fibrin provide not only stimuli thanks to the bioactive molecules 
contained in the platelets, but a provisional matrix for the cells as well114,116. The lack of 
standardization of the preparation methods in terms of number of the donors, anticoagulant 
agent, applied centrifugation speed and its duration, and a potential activation method. All the 
mentioned parameters affect the resulting blood derivative and the presence, concentration, 
protection, release, stability and diffusion of the contained bioactive molecules114. 
Generally, during the first step, the whole blood is processed using a “soft spin” (brief 
centrifugation at low acceleration) to obtain three layers: red blood cells, buffy coat layer 
(containing platelets and leucocytes) and the platelet-poor plasma (PPP). Then, the platelet-
poor plasma together with, depending on the desired final product, the superficial layer of the 
buffy coat (pure PRP) or the entire buffy coat (leucocyte-rich PRP) are transferred to a new 
tube. Following a “hard spin” (high acceleration), most of the PPP layer is discarded and the 
final product is the PRP117 (Figure 7). 
The platelet-poor derivatives include the platelet-poor plasma, a liquid of a very low 
cellular content (Figure 7A). Although the PPP is almost depleted of platelet-derived GFs, it 
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contains some GFs, such as HGF or IGF-1118. By clotting the PPP, the predecessor of today’s 
fibrin glue may be formed (Figure 7B). However, the adhesive qualities of the autologous fibrin 
glues were poor as the concentration of fibrinogen in the PPP was rather low119. With the 
improvement of isolation and concentration techniques of the clotting factors, the fibrin glue 
systems started to advance. There are several commercial products available in Europe, such 
as Tisseel® (Vienna, Austria), composed of a fibrinogen solution and a thrombin solution rich in 
calcium. The commercial fibrin sealants have improved mechanical properties compared to the 
autologous fibrin glues120, thanks to the higher fibrinogen content. 
Besides their application as haemostatic agents and tissue sealants, fibrin glues have been 
used as a drug delivery system, owing to its approval by the medical agencies. The properties 
of the fibrin sealants (fibre diameter, pore size) depend on the crosslinking time that can be 
varied by the concentration of the two components and by ionic strength of the thrombin solution 
121. Therefore, the release kinetics of the encapsulated bioactive molecules may be modified. 
Furthermore, fibrin serves as a reservoir for various growth factors122. Delivery of bFGF123 and 
VEGF124,125, TGF-β1126, or PDGF-AB127 was investigated, together with delivery of lidocaine for 
post-operative pain reduction128 or vancomycin to treat difficult infections129. Besides drugs, 
fibrin can be successfully used to deliver cells such as skeletal myofibroblasts130, human dermal 
fibroblasts131–133, or keratinocytes134,135. 
The platelet-rich plasma (Figure 7C) is defined as a volume of autologous plasma 
containing platelets at a concentration above their normal blood range (i.e. 150,000 platelets/µL 
to 450,000 platelets/µL)114. The platelet concentration has a major effect on the GF content and 
thus the therapeutic outcomes. Therefore, for clinical applications, the working definition of PRP 
is considered to be 1,000,000 platelets/µL (i.e. 3- to 7-fold increase in the normal blood platelet 
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concentration)136; all suspensions of platelets above the blood baseline are generally termed 
platelet concentrates. 
The PRP may be used directly, or it is possible to activate it by addition of e.g. thrombin or 
calcium salts. The activation results in formation of a fibrin clot containing the activated platelets 
(platelet gel) and the supernatant contains the released GFs (plasma rich in growth factors, 
PRGF) (see Figure 7G). The content of the GFs released to the supernatant is dependent of 
the method of activation and may vary114,118,137,138. Furthermore, the method of activation and 
coagulation degree also affect the resulting morphology and mechanical properties of the fibrin 
clot139, ranging from supplements of cell culture media140, to bioactive PRGF-coated dental 
implants141 or fibrillar scaffold-like structures for maxillofacial surgery142. A similar product, 
platelet-rich fibrin matrix (PRFM), was prepared by clotting the PRP during a high-speed 
centrifugation. The resulting PRFM was used to treat non-healing lower-extremities ulcers in a 
pilot study with promising results in terms of wound closure, as PRFM represents a safe, 
autologous and easy-to-use adjuvant modality143. Furthermore, a study performed in diabetic 
patients with a chronic non-healing diabetic ulcer compared the efficacy of PRP and PPP. The 
results showed that the healing of diabetic ulcers was significantly faster in case of PRP vs 
PPP144. 
Another blood derivative is the platelet lysate (PL) (Figure 7D). The platelet lysate is 
obtained via disruption of the platelet membranes using freeze/thaw cycles or ultrasound, 
resulting in a liquid rich in bioactive molecules114. The PL contains most of the GFs found in the 
other platelet-rich derivatives, however, the levels of some GFs (e.g. PDGF) are significantly 
lower145. Despite that, the PL offers several advantages: it is easier to standardize its 
preparation, as it only requires freeze/thaw cycles and no further activators; during the 
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processing, platelet debris or any clots are removed and thus the solution is highly unlikely to 
clot spontaneously; it can be frozen and stored for further use146. 
In regenerative medicine, the PL has multiple applications. It may be used in the form of a 
platelet lysate gel, following addition of a clotting agent (see Figure 7F). Platelet lysate gels 
have been used to treat chronic leg ulcer with encouraging results147, as a drug/cell delivery 
system to promote mesenchymal stem cells (MSCs) chondrogenesis148 or to foster endothelial 
progenitor cells proliferation and neovascularization149. Furthermore, platelet lysate gel was 
shown to possess antimicrobial activity150. The platelet lysate may also be loaded into various 
drug delivery systems to prolong the therapeutic efficacy of the GFs in vivo, as their half-time 
is generally very short (several minutes)151,152. Using drug delivery systems, high doses and/or 
frequent administration of the GFs may be prevented, lowering the toxicity and cost of a such 
therapy153. 
The platelet lysate also represents the prevailing alternative to the foetal bovine serum 
(FBS) for in vitro expansion of mesenchymal stem cells154 and multiple other cells108 in clinical 
applications. There are several risks associated with the FBS-supplemented cell culture, such 
as the risk of xeno-immunization, transmission of pathogens, or ethical issues in terms of the 
FBS collection155. The use of platelet lysate enables its large-scale manufacturing due to its 
possible allogeneic use. As was described above, the method of preparation influences the 
protein/GFs profile of the resulting products. Additionally, the characteristics of the donor (age, 
sex, platelet count, and diseases156) affect the GF content and the ability of the platelet 
derivative to induce the desired response108,155,157. Thanks to pooling of the platelet lysate, the 
interindividual variability of the platelet derivatives can be minimized. The storage conditions of 
the platelet lysate may be further improved by their lyophilisation, resulting in platelet 
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lyophilisate (Figure 7E); such supplement could provide an “of-the-shelf” product. The 
lyophilized platelet lysate showed to retain its biological properties when compared to the fresh 
platelet lysate158. Another advantage of the lyophilized platelet lysate is its possible 
reconstitution in various solvents during fabrication of drug delivery systems, and its possible 
further concentration. 
The final platelet derivative is the platelet rich fibrin (PRF) (Figure 7H). The second 
generation platelet-rich derivative does not require the second centrifugation step and no 
further clotting agents are added to the mix, as the PRF is produced by spontaneous clot 
formation120. Besides platelets, it also contains red blood cells and white blood cells, however, 
the determining element responsible for the clinical outcome is the fibrin matrix. The resulting 
fibrin membranes may be used for superficial cutaneous or mucous healing, however, due to 
its autologous origin, the amount of the PRF is limited159. The PRF shows promising results in 
healing of osseous defects, as fibrin serves a net for cells and promotes angiogenesis160. In 
chronic wound healing, the effect of PRF on epithelialization was investigated in a randomized 
clinical trial; no significant differences re-epithelialization rate in PRF vs no intervention were 
observed161. Furthermore, the study of growth factor levels in cell culture with the use of PRP 
and PRF was conducted and showed, that the PRP contained significantly more GFs vs 
PRF162. On the other hand, the release profiles of the GFs may be significantly different. In 
PRP, a clear decrease in release of TGF and PDGF was observed after day 1 versus their 
prolonged release for up to one and two weeks, respectively163. 
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2.5.3 Platelet derivatives and drug delivery systems 
The half-life of the growth factors (synthetic or natural) is generally very short (order of 
minutes). In vivo, their degradation or deactivation may be caused by their denaturation, 
oxidation or proteolysis, restricting their bioavailability114,164. Similarly to the naturally occurring 
fibrin matrix, biomaterial matrix would protect the soluble growth factors and prevent their fast 
clearance and/or diffusion from the site of administration and their degradation in the proteolytic 
environment13. Therefore, platelet derivatives have been combined in numerous applications 
in regenerative medicine / tissue engineering to control the spatial-temporal release profile of 
the entrapped growth factors. 
Several drug delivery systems were developed and tested in skin tissue engineering, 
ranging from polymeric micro- and nanospheres to nanofibres, hydrogels and other forms of 
gels, and their combinations165. For example, platelet lysate was successfully adsorbed to the 
surface of chitosan/chondroitin sulphate nanoparticles. The results showed release of the GFs 
contained in the platelet lysate for up to one week153. Furthermore, it was shown these PL-
enriched nanoparticles self-assemble into 3D hydrogel structures at high concentrations. In the 
system, a strong initial burst release of PDGF-BB and TGF-β1 (92% and 80% respectively) 
was observed on day 1166. Another study examined the loading of platelet-rich plasma 
(prepared by various centrifugation techniques) into a chitosan freeze-dried scaffolds, resulting 
either into a PRP-loaded gel or “sponge”. The release of the observed growth factors (PDGF-
BB, IGF-1, and TGF-β1) was prolonged to up to 20 days if the PRP was added to the chitosan 
prior to the freeze-drying and not applied to its surface during post-processing167. 
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Polymer nanofibres containing PRP were fabricated. Firstly, blend electrospun 
chitosan/polyethylene oxide (PEO) nanofibres containing platelet lysate were prepared and 
used to promote dermal cells proliferation. Although the majority (70%) of the enclosed platelet 
lysate was released within 3 hours (and the total content of the PL within 24 hours), the 
fabricated nanofibres fostered keratinocyte proliferation168. Coaxial electrospinning of 
PCL/PRGF solutions and co-electrospinning of a PCL solution and a PRGF solution (one 
common collector) were compared. The results showed sustained release of the incorporated 
proteins for up to 35 days, however, the coaxial electrospinning resulted in almost 6-fold 
increase in encapsulation efficiency when compared to the co-spinning technique169. Emulsion 
electrospinning of dextran-stabilized PRGF into PCL/gelatine nanofibres improved the release 
characteristics of the nanofibres. Still, a burst release was observed (50% of the enclosed 
content released approximately by day 5), however, the fibres maintained a sustained release 
of the observed growth factors (TGF-β1, FGF, and PDGF) for at least 30 days170. Furthermore, 
platelet alpha-granules were encapsulated into PCL/polyvinyl alcohol (PVA)γ core/shell 
nanofibres. The system was compared with platelets adhered to the surface of the PCL 
nanofibres; the concentration of TGF-β1 was used as a measure of the GFs released. On day 
1, the concentration of the released TGF-β1 was almost 6 times higher vs the incorporated 
coaxial samples, with the half-time of TGF-β1 release was 7 days. In contrast, the coaxial 
samples showed delayed release of the encapsulated content (50% of the enclosed TGF-β1 
was released by day 14)171. These results illustrate that the combination of platelet derivatives 
with a proper biomaterial may represent a suitable strategy to maximize the therapeutic 
potential of the plethora of bioactive molecules contained in platelets. 
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3 AIMS OF THE THESIS 
1. To investigate the effect of various bioactive molecules contained in the platelet lysate 
in skin cell (fibroblasts and keratinocytes) culture in a biomimetic environment with the 
use of nanofibrous scaffolds. To determine the optimum conditions for skin cell culture 
and optimize the culture protocols for FBS replacement. 
2. To develop a nanofibrous scaffold functionalized with platelets as a source of growth 
factors with possible application in wound healing and feasible translation to clinical 
practice. To demonstrate the potential of such system in vitro. 
3. To develop a platelet lyophilizate-loaded nanofibrous scaffold for long-term delivery of 
bioactive molecules derived from platelets. To compare two fibre-fabricating 
technologies, electrospinning and centrifugal spinning. To demonstrate the potential of 
such systems for tissue engineering applications in an in vitro study. 
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4 EXPERIMENTAL PART 
The experimental part of the manuscript is divided into three sections consisting of four 
experiments. 
In the first section of the experiments (Experiment 6.1), platelet lysate as a promising FBS 
replacement was investigated. Skin cell (fibroblasts and keratinocytes) culture using the platelet 
lysate was established using the biomimetic environment of electrospun PCL nanofibres. The 
obtained data confirm the suitability of the platelet lysate as an FBS replacement, highlight its 
potential for skin cell expansion, and thus, the proposed system composed of PCL nanofibres 
and PL may represent an efficient tool in skin tissue engineering. 
The second section of the experiments (Experiment 6.2) evaluated a simple system 
consisting of PCL nanofibres and platelets in their native form. Firstly, the PCL nanofibres 
prepared by electrospinning were functionalized by simple adhesion of platelets to the surface 
of the nanofibres. The potential of the system was evaluated using the skin cells (fibroblasts, 
keratinocytes, and melanocytes) and various concentrations of platelets. The main advantage 
of the platelet-functionalized nanofibres is the more sustained released of the bioactive 
molecules contained in the platelets, as the half-time of the growth factors itself is very short. 
Furthermore, the relatively easy preparation enables on-site preparation of the scaffold with the 
use of patient’s autologous platelets and thus potential clinical translation of the system to 
wound healing applications. 
The positive effect of the bioactive compounds contained in the platelets on melanocytes 
was further investigated in the third experiment of the manuscript (Experiment 6.3). Two fibre-
forming technologies (electrostatic and centrifugal spinning) were employed and compared and 
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the prepared fibrous scaffolds were functionalized with human native platelets. The 
functionalization of the surface of the centrifugal spun samples resulted in a 2-fold increase in 
the number of platelets adhered to the surface, and thus in the number of bioactive molecules 
within the platelets. Furthermore, detectable amounts of thrombospondin-1 and TGF-β1 were 
detected in the centrifugal spun system with the highest platelet concentration even after 14 
days, suggesting a significant improvement of the drug delivery concept. 
In the last section (Experiment 6.4), an emulsion-based drug delivery system for 
regenerative medicine applications was developed. The core/shell electrospun and centrifugal 
spun nanofibres were enriched by platelet lyophilizate. The lyophilization of the platelet lysate 
firstly overcomes the issues associated with the short life-span of native platelets and, 
furthermore, it facilitates the loading of the proteins into the fibrous systems, as it allows the 
solubilization of the proteins in suitable solvents. The study compared different composition of 
the fibres and the effect of the differing concentration of platelet lyophilizate released from the 
fibres on the seeded keratinocytes and fibroblasts. The results of the study indicated that the 
emulsion core/shell nanofibres are a suitable system for tissue engineering, delivering bioactive 
proteins in prolonged time scales. 
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5 MATERIALS AND METHODS 
5.1 Scaffold fabrication techniques 
The electrospun PCL scaffolds (used in the Experiments 6.1, 6.2 and 6.3) were fabricated 
using the Nanospider™ NS 500 device (Elmarco, Czech Republic). To perform the 
electrospinning process, a 24% (w/v) solution of PCL (MW 45,000; Sigma Aldrich, MO, USA) 
dissolved in a mixture of chloroform and ethanol (volume ratio 9:1) was used. The polymer 
solution was connected to the high-voltage source (Spellman HV, NY, USA). The voltage used 
for electrospinning was 70 kV, the distance was set at 35 cm and the polymer flow rate was 50 
mL/h. The solution was electrospun using a needleless wire electrode and the nanofibres were 
deposited on a non-woven supporting Spunbond textile (Pegas Nonwovens, Czech Republic). 
The conditions during the process were maintained at 23±2 °C and 60±15% relative humidity. 
The centrifugal spun PCL scaffolds (used in the Experiment 6.3) were fabricated using a 
centrifugal spinning device (Cyclone L-1000D Forcespinning® device; FibeRio, TX, USA). To 
perform the centrifugal spinning process, a 40% (w/v) solution of PCL (MW 45,000; Sigma 
Aldrich, MO, USA) dissolved in a mixture of chloroform and ethanol (volume ratio 9:1) was 
used. An orifice G30 at a rotation speed of 6,000 g was used to prepare the layers. The formed 
fibres were deposited on a non-woven textile (Pegas Nonwovens, Czech Republic) using 
vacuum-assisted deposition. 
The electrospun core/shell samples (used in the Experiment 6.4) were prepared using 
needleless emulsion electrospinning technique (water-in-oil emulsification, W/O). The shell of 
the fibres was made of PCL (MW 45,000, Sigma Aldrich, MO, USA) and the core of the fibres 
54 
 
consisted of poloxamer 188 Pluronic F68 (PF-68, Sigma Aldrich, MO, USA) combined with 
platelet lyophilizate. A 24% (w/v) PCL was prepared dissolving PCL in a mixture of chloroform 
and ethanol (volume ratio 9:1). Emulsification was performed with water phase containing the 
platelet lyophilizate dissolved in 50% ethanol and pure ethanol to achieve a core solution of 1% 
(w/v), 5% (w/v) or 10% (w/v) PF-68. The final core mixture contained 70% ethanol. Control PCL 
samples were prepared by electrospinning of 24% PCL, as described above. All samples were 
electrospun using a wire electrode using a Nanospider™ NS 500 device as described above. 
The precise composition of the samples is shown in Table 2. 
The centrifugal spun core/shell samples (used in the Experiment 6.4) were prepared using 
emulsion centrifugal spinning technology based on W/O emulsification. The shell of the fibres 
consisted of 40% PCL solution and the core of the fibres consisted of poloxamer 188 Pluronic 
F68 (PF-68, Sigma Aldrich, MO, USA) combined with platelet lyophilizate. The precise 
composition of the samples is given in the Table 2. The 30% (w/v) PF-68 dissolved in 90% 
ethanol was mixed with the platelet lyophilizate dissolved in 50% ethanol and pure ethanol, to 
achieve a solution of 1% (w/v), 5% (w/v) or 10% (w/v) PF-68. The mixing process was 
performed by drop-wise mixing of the lyophilizate to the agitated PF-68 solutions, followed by 
sonication. The final core mixture contained 70% ethanol. The mixture of PF-68 and the platelet 
lyophilizate was subsequently emulsified with 50% PCL dissolved in chloroform to obtain 40% 
PCL solution in a mixture of chloroform and ethanol at a volume ratio of 4:1. The ethanol phase 
was added drop-wise under stirring. The prepared emulsion was immediately processed by the 
centrifugal spinning process. The control sample was prepared by the spinning of 40% (w/v) 
PCL in a mixture of chloroform and ethanol at a volume ratio of 4:1. The centrifugal spinning 
was performed using the centrifugal spinning technology of the Cyclone L-1000D device 
55 
 
(FibeRio, TX, USA). All samples were processed by G30 needles at 11,000 RPM and a 
collector distance of 10 cm. The fibres were collected using a vacuum assisted deposition 
system to prepare more condensed samples. 
Table 2 Precise composition of the fabricated electrospun and centrifugal spun samples. 
5.2 Scaffold characterization using scanning electron microscopy 
The structure of the scaffolds fabricated in the Experiments 6.1, 6.2, 6.3 and 6.4 was 
visualized using scanning electron microscopy (SEM). The dry samples were sputter coated 
with gold using an Q150RS device (Quorum, UK). Vega3 SBU (Tescan, Czech Republic) 
microscope was used for image acquisition. The fibre diameter and pore size of the prepared 
samples was determined using ImageJ software from at least 200 independent measurements. 
5.3 Scaffold characterization via Fourier-transformation infrared spectroscopy 
The presence of the embedded platelet lyophilizate in the Experiment 6.4 was confirmed 
using Fourier-transformation infrared spectroscopy with attenuated total reflectance (FTIR-
ATR). The testing was performed on IRaffinity 1 system (Shimadzu, Japan). All samples were 
Sample Core polymer Shell polymer Platelet lyophilizate 
ES1 1% PF-68 24% PCL 15 mg/mL 
ES5 5% PF-68 24% PCL 15 mg/mL 
ES10 10% PF-68 24% PCL 15 mg/mL 
ES Control --- 24% PCL --- 
CS1 1% PF-68 40% PCL 15 mg/mL 
CS5 5% PF-68 40% PCL 15 mg/mL 
CS10 10% PF-68 40% PCL 15 mg/mL 
CS Control --- 40% PCL --- 
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moulded into tablets by 2t press. The measurement was performed in the range of 500–4,200 
cm-1 with Happ-Gazel apodization. 
5.4 Functionalization of the fibrous scaffolds with native platelets 
The surface of the prepared electrospun and centrifugal spun PCL samples was 
functionalized with different concentrations of platelets. The fabricated PCL samples (diameter 
6 mm) were punched out of the fibrous matts. The samples were sterilized using 70% ethanol 
and rinsed with PBS (three times). Fresh human leukocyte-poor platelet concentrate derived 
from buffy-coat (in additive solution) was obtained from Blood Transfusion Service (Šumperk, 
Czech Republic). The bag was prepared from blood of four donors. The platelet concentration 
in the bag in the case of Experiment 6.2 was 1,030x109 platelets/L, the platelet concentration 
in the bag in the case of Experiment 6.3 was 967x109 platelets/L. The platelet concentrations 
in the Experiment 6.2 are given in Table 6, the platelet concentrations in the Experiment 6.3 
are given in the  
. The solutions containing the appropriate concentration of platelets were prepared by 
diluting the platelet concentrate in SSP+ additive solution (Macopharma, France). In case of a 
solution with platelet concentration higher than the platelet concentration in the bag 
(Experiment 6.3), the platelet concentrate was firstly centrifuged (3,100 g for 10 minutes) and 
then resuspended in the appropriate volume of SSP+ to obtain the desired platelet 
concentration. Finally, 50 μl of the prepared solutions were added to the sterile nanofibrous 
samples in a 96-well plate. The samples were incubated for 2 hours at a temperature of 22 °C. 
Afterwards, the samples were washed with PBS and placed into new wells. 
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5.5 Platelet lysate preparation 
Platelet lysate was prepared for use in the Experiment 6.1. Fresh human leukocyte-poor 
platelet concentrate derived from buffy-coat (in additive solution) was obtained from blood 
transfusion service (Šumperk, Czech Republic). The platelet concentration in the bag was 
800x109 platelets/L. The bag was prepared from the blood of 16 donors to minimize 
interindividual differences. Platelet lysate (PL) was prepared using the freeze-thaw method. 
Briefly, the entire bag was frozen (-80 °C) and thawed (37 °C) three times in total to disrupt the 
platelets. Then, the solution was centrifuged (4,100 g for 15 minutes) to dispose of the cellular 
debris. The PL was stored at -80 °C until use. 
5.6 Platelet lyophilizate preparation 
Platelet lyophilizate was prepared for the Experiment 6.4. Fresh human leukocyte-poor 
platelet concentrate derived from buffy coat in additive solution was obtained from a blood 
transfusion service (Šumperk, Czech Republic). The platelet concentration in the bag was 
917x109 platelets/L. The bag was prepared from blood of four donors. The platelets were 
centrifuged (3,100 g, 10 minutes) and resuspended in distilled water. Subsequently, the 
solution was aliquoted, frozen (-80 °C) and thawed (37 °C) three times in total to disrupt the 
platelet cellular membranes. The platelet lysate was centrifuged (4,100 g for 15 minutes) to get 
rid of the cellular debris. Subsequently, the platelet lysate was lyophilized under 480 mTorr 
(VirTis BenchTop Pro Freeze Dryer, SP Scientific, PA, USA) for 24 hours. The lyophilized 
platelet lysate (platelet lyophilizate) was stored at -80 °C until use. 
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5.7 Bioplex analysis of bioactive molecules contained in platelets 
To characterize the cytokine content in the platelet lysate (Experiment 6.1), platelets 
(Experiment 6.3), and platelet lyophilisate (Experiment 6.4), the Bio-Plex 200 Multiplex System 
(Bio-Rad Laboratories, CA, USA) was employed. The commercially available cytokine panel 
(Bio-Plex ProTM Human Cytokine 27-plex Assay, Bio-Rad Laboratories, CA, USA) was used, 
in accordance with the manufacturer’s instructions. The assay allows multiple cytokines to be 
quantified simultaneously in one well. The following cytokines were quantified: interleukin-1b 
(IL-1b), interleukin 1ra (IL-1ra), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), 
interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin-10 
(IL-10), interleukin-12 (IL-12), interleukin-13 (IL-13), interleukin-15 (IL-15), interleukin-17 (IL-
17), granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony 
stimulating factor (GM-CSF), interferon-gamma (INF-γ), tumour necrosis factor-α (TNF-α), 
monocyte chemoattractant protein-1 (MCP-1), CXCL10 chemokine (C-X-C motif ligand-10), 
macrophage inflammatory protein-1a (MIP-1a), MIP-1b (C-C motif ligand-4, CCL-4), RANTES, 
eotaxin (CCL-11), platelet-derived growth factor (PDGF), basic-fibroblast growth factor (bFGF), 
and vascular endothelial growth factor (VEGF). 
5.8 Determination of total protein content 
The protein content in the platelet lysate (Experiment 6.1) and platelet lyophilizate 
(Experiment 6.4) was determined using Quant-iT™ Protein Assay Kit, (Invitrogen Life 
Technologies, CA, USA) in accordance with the manufacturer’s instructions. 
To determine the release profiles from the platelet lyophilizate-containing samples in the 
Experiment 6.4, total protein released from the samples was determined. The samples were 
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weighed (80 mg) and to each sample, 500 µL of PBS was added. The samples were kept at 
37 °C. On day 1, 3, 7 and 14 of the experiment, the PBS was collected, frozen (-80 °C) and 
replaced by new PBS. The concentration of total protein released from the samples was 
determined using Quant-iT™ Protein Assay Kit, (Invitrogen Life Technologies, CA, USA) in 
accordance with the manufacturer’s instructions 
5.9 Growth factor release from the platelet-functionalized samples 
To determine the release profiles of growth factors from the platelet-functionalized samples 
in the Experiment 6.2, EGF was chosen as a model molecule. On day 1, 3, 7 and 14 of the 
experiment, cell culture media were collected and frozen (-80 °C). The concentration of EGF 
released from platelets and/or synthetized by the seeded cells was quantified by the enzyme-
linked immunosorbent assay (ELISA) in accordance with the manufacturer’s instructions 
(DuoSet®; R&D Systems, MN, USA). 
To determine the release profiles of growth factors from the platelet-functionalized samples 
in the Experiment 6.3, TSP-1 was chosen as a model molecule. The samples were weighed 
(80 mg) and to each sample, 500 µL of PBS was added. The samples were kept at 37 °C. On 
day 1, 3, 7 and 14 of the experiment, the PBS was collected, frozen (-80 °C) and replaced by 
new PBS. The concentration of TSP-1 released from platelets adhered to the electrospun and 
centrifugal spun samples was quantified by the enzyme-linked immunosorbent assay (ELISA) 
in accordance with the manufacturer’s instructions (DuoSet®; R&D Systems, MN, USA). 
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5.10 Cell culture & cell seeding 
Murine XB2 cell line (keratinocytes) and murine melan-a cell line (melanocytes) were 
purchased from the Welcome Trust Functional Genomics Cell Bank at St. George’s, University 
of London, 3T3-A31 cell line (fibroblasts) from Sigma-Aldrich (MO, USA). The cells were 
cultured in a humidified incubator (37°C, 10% CO2 and 80–90% relative humidity). 
Keratinocytes and fibroblasts were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% FBS (Sigma Aldrich, MO, USA) and penicillin/streptomycin (100 IU/ml, 
100 μg/ml respectively) mixture. Melanocytes were cultured in RPMI-1640 medium 
supplemented with 10% FBS (Sigma Aldrich, MO, USA), penicillin/streptomycin (100 IU/ml, 100 
μg/ml respectively), 2 mM L-glutamine and 200 nM TPA (12-O-Tetradecanoylphorbol-13-
acetate) mixture. Sub-confluent cells were washed with PBS-EDTA solution and treated with 
0.05% trypsin. The scaffolds were seeded with cells at densities given in Table 3. The cell 
culture medium was supplemented with 10% FBS or 5% FBS during the experiment (precise 
cell medium composition is given in Table 3). 
Table 3 Summary of cell culture conditions. Cell culture conditions, sterilization techniques and cell seeding 





Cells Seeding density 
(cells/cm2) 
Medium change 
6.1 70% ethanol 10% Fibroblasts 14,200 Every 3 to 4 days 
Total volume Keratinocytes 14,200 
6.2 70% ethanol 10% Keratinocytes 7,800 Every 7 days 
Half of the volume Fibroblasts 7,800 
Melanocytes 12,500 
6.3 70% ethanol 10% Melanocytes 17,850 Every 7 days 
Half of the volume 
6.4 Ethylene oxide 5% Fibroblasts 17,850 Every 7 days 
Half of the volume Keratinocytes 17,850 
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5.11 Cell metabolic activity testing 
On experimental days, the metabolic activity of cells was determined using the MTS assay 
(CellTiter96® AQueous One Solution Cell Proliferation Assay; Promega, WI, USA). To each 
scaffold, 20 μl of MTS solution and 100 μl of fresh medium were added. After incubation (37°C, 
10% CO2, 80-90% relative humidity; 2-hour for keratinocytes and fibroblasts, 3-hour for 
melanocytes) the absorbance of the media was detected at 490 nm with a microplate reader 
(Infinite® M200 PRO; Tecan, Switzerland). The background absorbance (690 nm) was 
subtracted from the measured data, as well as the absorbance of plain media. Platelets contain 
mitochondrial enzymes and thus metabolize the MTS substrate. To exclude misrepresentation 
of the cell metabolic activity due to the presence of platelets on the surface of nanofibres, an 
MTS assay of samples with platelets was performed (for Experiment 6.2 and 6.3). The detected 
absorbance was subtracted from the measured data. The summary of performed tests and 
experimental days within the individual experiments is given in Table 4. 
5.12 Cell proliferation testing 
Cell proliferation was determined on the experimental days using a fluorescence-based kit 
(Quant-iT™ PicoGreen® dsDNA Assay Kit, Invitrogen Life Technologies, CA, USA). The 
samples used for the MTS assay were transferred to cell lysis buffer (10 mM Tris, 1 mM EDTA, 
0.2% v/v Triton X-100). To facilitate the cell lysis and DNA release, the samples underwent 
three freeze/thaw cycles. In between the cycles, the samples were vortexed. Fluorescence 
intensity was detected using the microplate reader (Infinite® M200 PRO; Tecan, Switzerland; 
λex = 485 nm, λem = 528 nm) and the DNA content was determined according to the λDNA 
62 
 
calibration curve of the kit. The summary of performed tests and experimental days within the 
individual experiments is given in Table 4. 
5.13 Melanin content determination 
Melanin content on the scaffolds was determined using the alkali extraction method in the 
Experiment 6.2 on day 1, 3, 7 and 14. The nanofibrous samples with seeded cells were 
transferred to 300 μl of 1 M NaOH and incubated for 2 hours at 80 °C. Afterwards, the samples 
were vortexed to facilitate solubilization of melanin and centrifuged (10,000 g, 1 minute, 
MiniSpin®, Eppendorf) to sediment the PCL debris. Absorbance of the supernatant was 
detected at 405 nm using a microplate reader. The melanin content on the scaffolds was 
determined according to a calibration curve (synthetic melanin, Sigma-Aldrich, MO, USA). 
5.14 Cell visualization using confocal microscopy 
Confocal microscopy was used to visualize the cells. The cells seeded on scaffolds were 
fixed with methanol (-20°C), rinsed with PBS and stained. DiOC6(3) was used to visualize the 
cellular membranes (1 μg/ml in PBS, 30 minute) and propidium iodide (5 μl/ml, 10 minute) to 
visualize the cell nuclei. Between the incubations the samples were rinsed with PBS. A Zeiss 
LSM 510 DUO confocal microscope was used for imaging (λex maximum = 488 nm, λem 
maximum = 501 nm for DiOC6(3); λex maximum = 536 nm, λem maximum = 617 nm for 
propidium iodide). In case of melanocytes, confocal images were merged with images scanned 
in visible light to visualize the melanin present on the scaffolds. 
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5.15 Cell visualization using scanning electron microscopy 
To visualize the cells adhered on the scaffolds, SEM was used. Platelets adhered to the 
surface were visualized after 2-hour incubation in Experiments 6.2 and 6.3. The keratinocytes 
and fibroblasts cultured on the platelet-lyophilizate scaffolds were visualized using SEM on day 
7 in Experiment 6.4. The samples were fixed with 2.5% glutaraldehyde (Sigma-Aldrich, MO, 
USA) at 4 °C. After 2 hours, the samples were dehydrated with ethanol changes (35%, 48%, 
70%, 96% and 100% ethanol). Hexamethyldisilazane (Sigma-Aldrich, MO, USA) was used to 
remove any residual water from the samples. The samples were sputter-coated with gold (app. 
30 nm) and visualized using Vega 3 SBU microscope (Tescan, Czech Republic). 
5.16 Statistical analysis 
The acquired data were statistically evaluated using SigmaStat 3.5 software. To test the 
normality of the data Kolmogorov-Smirnov test was used; to test the equality of variances 
Levene’s test was used. In case the data passed the normality test and the test of equality of 
variances, statistical significance between a pair of groups was determined using ANOVA 
testing. Tukey’s comparative test was used for post-hoc analysis. Statistical significance 
between a pair of groups without normal distribution was determined by conducting Kruskal-
Wallis test and using Dunn’s multiple comparisons test for post hoc analysis. The data are 




5.17 Summary of performed tests 
For the sake of clarity, the performed tests in the individual experiments are summarized 
below in Table 4. 







6.1 D1, D3, D7, 
D10 
D1, D3, D7, 
D10 
D1, D7, D10 --- --- 
6.2 D1, D3, D7, 
D14 
D1, D3, D7, 
D14 
D1, D7, D14 Scaffolds with 
platelets after 
2-hour incubation 
D1, D3, D7, D14 
6.3 D1, D3, D7, 
D14 
D1, D3, D7, 
D14 
D7, D14 Scaffolds with 
platelets after 
2-hour incubation 
D1, D3, D7, D14 
6.4 D1, D3, D7, 
D14, D17 
D1, D7, D14, 
D17 




6 RESULTS AND DISCUSSION 
6.1 Platelet lysate as a serum replacement 
Given the issues associated with the use of xenogeneic FBS for human cell expansion in 
clinical practice, a possible FBS alternative was investigated. Platelet lysate was used to verify 
the effect of the growth factors contained in the platelets on skin cells. Platelet lysate was used 
as an FBS replacement (cell culture medium supplemented with platelet lysate only) and in 
combination with FBS (cell culture medium supplemented with combination of platelet lysate 
and FBS). Different platelet lysate and FBS concentrations were used and their effect was 
evaluated. The skin cells (murine keratinocytes XB2, fibroblasts 3T3-A31, and melanocytes 
melan-a) were cultured on PCL nanofibres prepared by needleless electrospinning, to mimic 
the natural microenvironment of the cells. For simplicity, Table 5 illustrates the names of the 
samples used within the manuscript. 
Table 5 Summary of sample coding used in the manuscript. 
Sample FBS content (%, v/v) Platelet lysate content (%, v/v) 
0F2.5L 0% 2.5% 
0F5L 0% 5% 
0F7L 0% 7% 
0F10L 0% 10% 
10F0L 10% 0% 
5F2.5L 5% 2.5% 
5F5L 5% 5% 
5F7L 5% 7% 
5F10L 5% 10% 
5F0L 5% 0% 
66 
 
6.1.1 Characterization of the scaffold 
The structure of the fabricated PCL nanofibrous scaffolds were visualized using scanning 
electron microscopy. The stereological measurements in the ImageJ software showed a 
combination of nano- and microfibres with minimum of non-fibrous defects. The mean diameter 
of the thin nanofibrous fraction was 229 ± 79 nm, and the thicker fibres had a mean diameter 
of 579 ± 133 nm. In addition, a fraction of less abundant microfiber fraction was detected with 
a mean diameter of 2,442 ± 925 nm. The porosity of the nanofibrous scaffold was determined 
to be 38 ± 3%. 
6.1.2 Characterization of the platelet lysate 
The content of the platelet lysate was characterized. The total protein, albumin and 
fibrinogen levels were determined, together with specific mediators using the XMAP technology 
and ELISA (Figure 8). 
 
Figure 8 Proteins and specific mediators contained in the platelet lysate. Graphical illustration of the relative 
composition of the assayed proteins and mediators in the platelet lysate172. 
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The Figure 8 illustrates that the concentrations of the monitored bioactive molecules were 
negligible in comparison to the total protein content of the platelet lysate. Nevertheless, most 
of the monitored analytes occurred at concentrations sufficient to fulfil their physiological 
functions. 
The platelet lysate contained various anti-inflammatory and pro-inflammatory cytokines, 
chemokines, and growth factors. The most abundant anti-inflammatory cytokine was IL-1ra 
(235.87 ± 4.77 pg/mL), a cytokine known to modulate a variety of immune and inflammatory 
responses. Other anti-inflammatory interleukins, such as IL-4, IL-10 and IL-13, were found at 
significantly lower concentrations. Similar concentrations of pro-inflammatory interleukins, such 
as IL-8, IL-9, IL-12, and IFN-γ and TNF-α, were detected (100–200 pg/mL). High concentration 
of interleukin 17 was observed (1,022.52 ± 56.43 pg/mL). However, very low concentrations of 
other pro-inflammatory cytokines (IL-1b, IL-6, IL-2, IL-5, IL-15), anti-inflammatory cytokines (IL-
4 and IL-13) and MIP-1a were observed. RANTES was the most abundant cytokine found in 
the platelet lysate. Its concentration was 10,000-times higher when compared to the 
concentration of other cytokines and chemokines. Additionally, there were growth factors 
detected in the PL. The most abundant growth factor detected was PDGF-BB. Furthermore, 
EGF and HGF were present at concentrations higher than 500 pg/mL. The analysis showed 
that the concentrations of GM-SCF and G-CSF were low compared to the concentration of 
other growth factors. The Figure 9 summarizes the concentrations of the assayed pro-
inflammatory and anti-inflammatory mediators together with the concentrations of chemokines 




Figure 9 Concentration of the assayed mediators in the platelet lysate. The mediators detected using the XMAP 
technology are depicted in dark grey colour, the mediators detected using ELISA in light grey colour172. 
Up to now, platelet lysate is one of the most promising FBS replacements, being used in 
various cell types culture ranging from hMSC to myofibroblasts and fibroblasts173–176. However, 
it suffers from considerable donor-to-donor variability. The variability was tested in hMSC 
culture, showing significant differences in hMSC proliferation when supplemented with PL from 
various patients177. To reduce the variability, the platelet lysate used in our studies was 
prepared from 16 donors. Bioactive molecules contained in the PL concentrations were 
determined using a multiplex XMAP technology. Another study used the multiplex assay to 
evaluate the content of the bioactive molecules in PRP178. Their analysis detected very similar 
levels of most of the anti- and pro-inflammatory cytokines, chemokines and growth factors, with 
the differences attributing to the donor-to-donor variability. The study investigated samples from 
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10 female donors and 6 male donors. The only significant difference was detected in the levels 
of PDGF-BB, with PDGF-BB levels being significantly higher in male donors when compared 
to the female donors. This may be explained by the fact that the platelet function may be 
influenced by gender, race or diet179. 
The proper ratio of pro- and anti-inflammatory cytokines, chemokines and growth factors is 
crucial for the precise regulation of physiological healing. The most abundant anti-inflammatory 
cytokine was IL-1 receptor antagonist (IL-1ra). The lack of IL-1ra leads to prolonged 
inflammation and causes a delay in the wound healing process180. Very similar proportion of 
anti-inflammatory cytokines, with IL-1ra present at the highest concentration, was observed in 
the PRP178. 
Pro-inflammatory cytokines such as IL-1b and IL-6 were observed at low concentrations in 
the PL. The most abundant pro-inflammatory cytokine detected in the PL was IL-17. IL-17 
mediates pro-inflammatory responses and contributes to neutrophil and monocyte recruitment. 
Recent studies assume that IL-17, derived from innate and adaptive sources, may act against 
various pathogens at different phases and locations of infection, pointing out the complexity of 
immune response181. Furthermore, IL-17 and TNF modulate expression of melanocyte 
mitogens (CXCL1, IL-8, IL-6, CXCL2, CXCL3 or BDNF), which may affect proliferation and 
growth of melanocytes182. 
The most abundant chemokine was RANTES. It plays role in attraction of many different 
cell types and accelerates the regenerative processes183. RANTES plays an active role in 
recruiting T-cells, eosinophils, basophils, and in the activation of natural killer cells at the site 
of inflammation. A similarly high concentration of RANTES was measured not just in our PL, 
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but also in the PRP. In the PRP, the RANTES concentration was even 2-times higher than in 
the PL178,184. 
Furthermore, the PL contained various growth factors that are essential for stimulation of 
skin cell proliferation and ECM production. For example, PDGF-BB, which plays an important 
role in wound healing, re-epithelization and tissue remodelling, was found at the highest 
concentration185. Interestingly, the concentration detected in the platelet lysate was almost 10-
times higher when compared to the PDGF-BB levels detected in the PRP178. The levels of 
PDGF-BB were established also in PRGF, where similar results in PDGF-BB concentrations 
were observed118. Furthermore, EGF was detected at a concentration higher than 500 pg/mL, 
which was in concordance with levels detected in the PRGF when expressed as the amount of 
EGF per 106 platelets118. EGF significantly stimulates keratinocyte proliferation and enhances 
their migration in acute wounds29. During angiogenesis, endothelial cells can undergo 
proliferation, which is stimulated by the vascular endothelial growth factor (VEGF), IL-8, and 
eotaxin186,187. The observed differences among the various preparations further reinforce the 
need for standardization of the preparation procedure in order to make any comparisons 
feasible118,178. 
6.1.3 In vitro activity of fibroblasts supplemented with platelet lysate 
The effect of the platelet lysate was on the cultured fibroblasts was determined by 




Figure 10 Metabolic activity and proliferation of fibroblasts. A – Metabolic activity of fibroblasts was measured by 
MTS assay (statistical analysis p < 0.05), B – Proliferation of fibroblasts determined by PicoGreen® assay (statistical analysis 
p < 0.05). The sample name (XFYL) codes the supplement concentration in the medium; X stands for concentration of FBS 
(v/v), Y for concentration of PL (v/v). The numbers above the bars indicate statistical significance172. 
The metabolic activity was gradually increasing in the groups 0F10L, 10F0L, 5F2.5L, 5F5L 
and 5F7L. The viability of the cells cultured in groups supplemented with 0F2.5L, 5F10L and 
5F0L increased until day 7, and then rather stagnated or declined. The results indicated that 
7% platelet lysate or higher was sufficient to replace the FBS. There was no statistically 
significant difference between the groups containing either 10% FBS (10F0L) or 10% platelet 
lysate (0F10L). In the groups containing the combination of FBS and PL, a lower concentration 
of PL (up to 7%) resulted in improved cell viability until day 3, whereas in the group with the 
highest concentration of PL (5F10L), the cell metabolic activity rapidly increased on day 7. 
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Furthermore, it was shown that low concentration (2.5%) of PL in combination with 5% FBS 
(5F2.5L) yielded better effect in regard to the metabolic activity of fibroblasts compared to the 
samples with a higher concentration of lysate when combined with FBS. We assume that the 
higher concentrations of growth factors and bioactive molecules contained in FBS and the PL 
resulted in rather inhibitory effect in the fibroblast culture. 
Additionally, proliferation of fibroblasts seeded on the electrospun nanofibrous PCL 
scaffolds was determined (Figure 10B). The most pronounced proliferation of the 3T3 fibroblast 
was detected in groups containing high concentration of either FBS or the platelet lysate, i.e. in 
the groups 0F7L, 0F10L and 10F0L. The groups with a combination of FBS and PL, or 5% FBS 
and low concentrations of PL (0F2.5L and 0F5L) alone, showed low proliferation activity 
throughout the entire experiment. The results were in concordance with the results of the MTS 
assay, and showed that 7% and higher concentration of PL could stimulate fibroblast 
proliferation better than the 5% FBS. 
Confocal microscopy was used to visualize the cells adhered to the nanofibrous scaffolds. 
The cells were well spread on the scaffold, exhibiting morphology typical for fibroblasts (Figure 
11). According to the images, the bioactive molecules supported gradual proliferation from day 
1 until day 10. In the case of the FBS-free groups, the cells supplemented with a low 





Figure 11 Confocal microscopy images of the fibroblasts seeded on the PCL scaffolds. The fibroblasts were 
observed on day 1, 7 and 10. Green colour depicts cellular biologic membranes (staining by DiOC6(3)), red colour cell nuclei 
(propidium iodide staining). Magnification 200x, scale bar 50 µm. The sample name (XFYL) codes the supplement 
concentration in the medium; X stands for concentration of FBS (v/v), Y for concentration of PL (v/v)172. 
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The obtained data indicate that the concentration of PL higher than 7% (v/v) promoted cell 
metabolic activity and proliferation and thus was suitable as an FBS replacement. However, 
the combination of FBS and the platelet lysate resulted in inhibition of the cultured fibroblasts. 
The effect of different concentrations of PL in a serum free-medium was investigated, in 
comparison with medium supplemented with the FBS for fibroblasts expansion. The study 
showed that the attachment of the cells to the plastic surface of a culture plate was faster in the 
case of FBS, however, the population doubling time was longer than in the PL-supplemented 
medium188. Another study investigated the effect of various concentrations of PL when added 
to a medium containing FBS and a serum-free medium. The results showed a dose-dependent 
effect of the PL, with a more pronounced stimulatory effect in the serum-free medium189. The 
dose-dependent effect of PL was confirmed also by our data showing dose-dependent 
proliferation of fibroblasts cultured in a medium supplemented with PL only and with 
combination of FBS and PL. The positive effect in the serum free-medium was increasing with 
the increasing PL concentration, while increasing concentration of the PL in the medium 
containing FBS resulted in decrease in the cell metabolic activity and proliferation. 
6.1.4 In vitro activity of keratinocytes supplemented with platelet lysate 
To investigate the effect of platelet lysate in keratinocytes culture, keratinocytes were 
seeded on PCL scaffolds and the culture was supplemented with platelet lysate and/or FBS. 




Figure 12 Metabolic activity and proliferation of keratinocytes. A – Metabolic activity of keratinocytes was 
measured by MTS assay (statistical analysis p < 0.05), B – Proliferation of keratinocytes was determined by PicoGreen® 
assay (statistical analysis p < 0.05). The sample name (XFYL) codes the supplement concentration in the medium; X stands 
for concentration of FBS (v/v), Y for concentration of PL (v/v). The numbers above the bars indicate statistical significance172. 
The metabolic activity was significantly increasing in groups supplemented with both the 
FBS and PL from day 3 to day 7 (Figure 12B). However, we did not observe a further increase 
in the metabolic activity between days 7 and 10. In the groups where only PL was added, a 
dose-dependent increase in metabolic activity and a high increase from day 7 to day 10 was 
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observed. The cells responded well to the cell culture conditions, and the 7% concentration of 
lysate (0F7L) was sufficient to replace the FBS. 
The amount of DNA was continuously increasing throughout the experiment (Figure 12B). 
The highest amount of DNA was detected in the group with the highest FBS and PL 
concentration (5F10L). Moreover, with the increasing concentration of the PL samples 
supplemented with PL and FBS (5F5L, 5F7L, 5F10L), statistically significant differences were 
observed on day 7. These differences were significantly improved not only in comparison with 
the group supplemented with 5% FBS, but even with the group with 10% FBS. 
The data obtained by the metabolic activity and proliferation testing were confirmed by 
visualization of keratinocytes via confocal microscopy (Figure 13). The samples showed almost 
confluent cell layers in the groups containing both the PL and FBS. The number of cells cultured 
in the serum-free medium supplemented with the PL only was increasing with the PL 
concentration. The presence of FBS stimulated cell contact and cells formed large clusters on 
the scaffolds, suggesting a rather stimulatory effect of the supplement mixture, in contrast to 




Figure 13 Confocal microscopy images of the keratinocytes seeded on the PCL scaffolds. The keratinocytes 
were observed on day 1, 7 and 10. Green colour depicts cellular biological membranes (staining by DiOC6(3)), red colour 
cell nuclei (propidium iodide staining). Magnification 200x, scale bar 50 µm. The sample name (XFYL) codes the supplement 
concentration in the medium; X stands for concentration of FBS (v/v), Y for concentration of PL (v/v)172. 
According to obtained data, the bioactive substances released from the PL positively 
influenced the proliferation and viability of the cultured keratinocytes. The dose-dependent 
effect of PL on cell proliferation was observed in both types of media (in media supplemented 
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with the PL only and in media supplemented with the combination of FBS and PL). However, 
PL concentration of 5% or higher was able to replace FBS in the serum-free conditions. The 
observed stimulatory effect was dose-dependent, which was in concordance with findings of a 
study evaluating primary human keratinocyte culture with different concentrations of PRP. The 
best proliferation rate was reached when using 10% PRP190. In contrast with the behaviour of 
fibroblasts, a positive dose-dependent effect of combination of both supplements, and thus 
higher concentration of the bioactive molecules, was observed. 
6.1.5 Summary 
The study evaluating the effect of bioactive molecules contained in the platelet lysate on 
skin cells showed, that 7% platelet lysate was able to replace FBS in both cultures of fibroblasts 
and keratinocytes. However, there were differences in cell behaviour when the cell culture 
medium was supplemented with both the FBS and platelet lysate (increased concentration of 
bioactive molecules). The cultured fibroblasts responded to the increasing concentration of 
bioactive molecules negatively, showing rather inhibition of their metabolic activity and 
proliferation. On the other hand, the increased concentration of bioactive molecules stimulated 
cell contact and resulted in improvement of keratinocyte metabolic activity and proliferation. 
6.2 Functionalization of electrospun PCL nanofibres with native platelets 
To improve the retention of bioactive molecules released from platelet at the site of 
application, a simple delivery system was proposed. The system consisted of PCL nanofibrous 
mesh and platelets adhered to the surface of the mesh. The PCL nanofibrous scaffolds were 
prepared by needleless electrospinning. Furthermore, they were functionalized with native 
human leucocyte-poor buffy coat-derived platelets at concentration P1 (the maximum platelet 
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concentration 1,030x109 platelet/L), P0.5 (half the maximum concentration 515x109 platelets/L) 
and P0.25 (quarter the maximum concentration 258x109 platelets/L). The effect of the released 
platelet-derived molecules was investigated using murine keratinocytes XB2, fibroblasts 3T3-
A31, and melanocytes melan-a. The composition of the samples is summarized in Table 6. 
Table 6 Composition of the electrospun samples functionalized with platelets in the Experiment 6.2. 
Sample Platelet concentration 
P1 1,030x109 platelets/L 
P0.5 515x109 platelets/L 
P0.25 258x109 platelets/L 
 
6.2.1 Characterization of the scaffold 
The architecture of the fabricated electrospun scaffolds was investigated using scanning 
electron microscopy (Figure 14). The samples showed architecture typical for PCL nanofibers. 
The analysis showed nano-/microarchitecture with a minimum of non-fibrous defects. The 
mean diameter of the thin nanofibrous fraction was 241.6 ± 90.6 nm, the thicker fibres had a 
mean diameter of 748 ± 147.4 nm. In addition, a less abundant microfibrous fraction was 
detected with a mean diameter of 1486.8 ± 419.1 nm. The mean pore size was 10.28 ± 12.1 
μm. On the platelet-functionalized samples, platelets were activated due to their contact with 
the nanotopography of the prepared nanofibrous layer and subsequently changed their 
morphology. Furthermore, a clear thick fibrin layer was observed on the platelet-functionalized 
PCL samples (Figure 14A-C). 
Similar architecture of the prepared fibrous samples was observed191. The nano-
/microstructure combines the advantages of larger pore size between the microfibers with the 
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high adhesion capacity of the nanofibrous part192. Importantly, we have demonstrated efficient 
adhesion of the platelets to the surface of PCL nanofibers. 
 
Figure 14 Scanning electron microscopy of the PCL nanofibrous samples with adhered native platelets after a 
two-hour incubation. A – P1 sample: PCL nanofibrous scaffold functionalized with the maximum platelet concentration, 
scale bar 20 µm, magnification 4,000x. B – P0.5 sample: PCL scaffold functionalized with half the maximum platelet 
concentration, scale bar 20 µm, magnification 4,000x. C – P0.25 sample: PCL scaffold functionalized with quarter the 
maximum concentration of platelets, scale bar 20 µm, magnification 4,000x. D – PCL control sample, scale bar 20 µm, 
magnification 2,940x193. 
Scanning electron microscopy images revealed that the platelets were activated upon 
adhesion to the scaffold surface and a thick fibrin network was formed. Such findings are in 
agreement with another study194. The study showed that platelets undergo activation upon 
adhesion to nanofibers thanks to their specific surface topography. The natural character of 
fibrin has been widely used in various tissue engineering applications. The fibrin network fosters 
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adhesion of cells via integrin and non-integrin receptors195. Such biomimetic motives are crucial 
for the enhancement of cellular adhesion and proliferation on the rather hydrophobic surface of 
PCL scaffolds. A similar system composed of platelets adhered to PCL nanofibrous mesh was 
tested by191,196. Jakubova et al. (2011) investigated optimum duration of the incubation period 
of nanofibre with platelet-rich solution, showing that prolonging the incubation period beyond 
two hours did not significantly increase the platelet adhesion efficiency. Furthermore, the study 
investigated the effect of surface adhesion of platelets to primary chondrocytes. Plencner et al. 
(2015) utilized such a system in ventral hernia regeneration. Both studies showed a significant 
improvement of cell metabolic activity and proliferation due to the bioactive substances 
released from platelets. 
Platelets are anucleated cells, however, they still possess mitochondria and thus could 
misrepresent the collected data. Therefore, the viability of the platelets adhered to the surface 
of nanofibres was evaluated on day 1, 3, and 7 (Figure 15). 
 
Figure 15 Metabolic activity of the platelets adsorbed to the surface of nanofibres. The MTS assay was performed 
on day 1, 3, and 7. 
The acquired data showed that the metabolic activity of the platelets adsorbed to the 
surface of PCL nanofibres is almost negligible. Some metabolic activity was detected on the 






























lowest tested platelet concentration (P0.25), there was no metabolic activity of platelets 
detected. Still, the acquired values were subtracted from the values acquired from the cell-
seeded samples to prevent misrepresentation of the data. 
6.2.2 Release characteristics of the bioactive molecules 
To characterize the release of bioactive molecules from the functionalized samples, levels 
of EGF as a model molecule were detected, as the EGF plays a key role in the wound healing 
process. The obtained data are shown as cumulative (Figure 16) and relative (Figure 17) 
release of the EGF, with cumulative graphs illustrating the absolute concentrations of the EGF 
detected in the culture media of the respective cell types and relative graphs illustrating the rate 
of release of the EGF from the platelet-functionalized samples. The cell culture media were 
collected on day 1, 3, 7, and 14 of the experiment and the EGF concentration was determined 
using ELISA. 
The cumulative release of EGF showed similar patterns among the three types of the 
cultured cells. The highest EGF concentration was detected in the P1 sample and the EGF 
concentration was accordingly lower at the samples P0.5 and P0.25. During the experiment, 
synthesis of EGF was observed in the keratinocyte culture (since day 7, Figure 16A) and 
fibroblast culture (since day 1, Figure 16B). However, the levels of EGF detected in the control 
samples were significantly lower than the concentration of EGF delivered by the adhered 




Figure 16 Cumulative release of EGF from the platelet-functionalized PCL samples. The levels of EGF in the cell 
culture media were detected using ELISA on day 1, 3, 7, and 14. A –The cumulative release of EGF detected in the 
keratinocyte culture. B – The cumulative release of EGF detected in the fibroblast culture. C – The cumulative release of 
EGF detected in the melanocyte culture. The name of the sample above the time-points in the graph denotes statistical 
significance; p<0.05193. 
EGF has been shown to stimulate proliferation of keratinocytes and fibroblasts197. 
Furthermore, it has been reported that sufficiently high concentrations of EGF result in 
keratinocyte differentiation, promoting wound healing in diabetic mice95. In the melanocyte 




Figure 17 Relative release of EGF from the platelet-functionalized PCL samples. The levels of EGF in the cell 
culture media were detected using ELISA on day 1, 3, 7, and 14. A –The relative release of EGF detected in the keratinocyte 
culture. B – The relative release of EGF detected in the fibroblast culture. C – The relative release of EGF detected in the 
melanocyte culture193. 
The relative release of EGF in the platelet-functionalized samples was very similar in all the 
platelet-functionalized samples, regardless of the initial platelet concentration. The median half-
time of release of the EGF (i.e. the time point, when 50% of the EGF was released) was 
1.7 days (range 1.3 to 2.1 days; Table 7). 
Table 7 Half-time of EGF release from the platelet-functionalized samples. The table represents the time to release 
of 50% of the contained EGF in days in the various cell cultures. 
Several similar systems for delivery of platelet-derived bioactive molecules have been 
developed. A system composed of PCL nanofibres coated with platelet lysate was described198. 
Sample Keratinocytes (days) Fibroblasts (days) Melanocytes (days) 
P1 1.6 1.3 1.9 
P0.5 2.0 1.3 2.1 
P0.25 1.7 1.5 2.0 
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The PCL scaffolds were incubated with the platelet lysate and then the PRP-coated PCL 
scaffold was freeze-dried. The performed release characteristics showed a significant burst 
release of the total protein (86% of the total protein released within 4 hours) and VEGF. The 
release of PDGF-BB and TGF-β1 was slower, however, 50% of the enclosed PDGF-BB and 
TGF-β1 were released by the system in less than the first 24 hours. Similar results (with release 
of GFs ranging from 75% to 85% within the first hour) were observed in a study evaluating 
titanium surfaces of implants covered with activated (thrombin, calcium chloride) or non-
activated platelet-poor plasma and plasma rich in growth factors199. 
The more sustained release of the growth factors observed in our study may be due to the 
thick fibrin network formed on the surface of the PCL scaffolds. The native platelets were 
activated due to the contact with the topography of the nanofibres and the 2-hour incubation 
allowed the fibrin network to be formed. It has been shown fibrin serves as a reservoir of several 
growth factors, including bFGF, TGF-β1, PDGF or IGF-1200–203. The fibrin-GF interaction could 
slow down the release of the captured growth factors. 
6.2.3 Keratinocytes seeded on the platelet-functionalized scaffolds 
To test the biocompatibility of the scaffolds, the metabolic activity of the seeded cells on 
platelet-functionalized scaffolds was determined. The Figure 18A shows the metabolic activity 
of keratinocytes. During the experiment there was no clear tendency in the acquired data. On 
day 14 the metabolic activity of keratinocytes was significantly higher on the P0.25 sample 




Figure 18 Keratinocyte metabolic activity and proliferation. A – Metabolic activity of keratinocytes measured by 
MTS assay (statistical analysis p<0.05). B – Proliferation of keratinocytes determined by dsDNA fluorescence assay 
(statistical analysis p<0.05). The level of significance is denoted by the numbers above the bars in the graph, number 1 
representing the P1 scaffold, 2 the P0.5 scaffold, 3 the P0.25 scaffold and 4 the PCL control scaffold. 
Proliferation of keratinocytes seeded on nanofibrous scaffolds is shown in Figure 18B. Until 
the day 14, there were no significant differences in keratinocyte proliferation among the 
samples. On day 14, all the samples containing platelets exhibited a significant increase in cell 
proliferation in comparison to the plain PCL. Furthermore, there were significant differences 
among the platelet-functionalized samples. On the P1 sample, the amount of the synthetized 
DNA was significantly larger in comparison to the P0.5 and P0.25 samples. 
The keratinocytes seeded on the samples were visualized using laser scanning confocal 




Figure 19 Confocal images of keratinocytes seeded on the platelet-functionalized samples. Cellular membranes 
were stained by DiOC6(3) (green colour), cell nuclei using propidium iodide (red colour). A1 – P1 scaffold on day 1, A7 – P1 
scaffold on day 7, A14 – P1 scaffold on day 14, B1 – P0.5 scaffold on day 1, B7 – P0.5 scaffold on day 7, B14 – P0.5 
scaffold on day 14, C1 – P0.25 scaffold on day 1, C7 – P0.25 scaffold on day 7, C14 – P0.25 scaffold on day 14, D1 –PCL 
scaffold on day 1, D7 –PCL scaffold on day 7, D14 –PCL scaffold on day 14. A1, B1, C1, D1 – scale bar 100 μm, 
magnification 200x, A7, A14, B7, B14, C7, C14, D7, D14 – scale bar 100 μm, magnification 150×193. 
On day 14, the keratinocyte monolayers were confluent on all the samples containing 
platelets. On the contrary, the number of cells on the plain PCL control sample did not increase 
so dramatically between day 7 and 14 of the experiment. 
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The results indicate that the released growth factors stimulated metabolic activity and 
proliferation on the platelet-functionalized samples in comparison to the plain PCL scaffold. 
However, the stimulatory effect on keratinocytes seemed to be independent of the initial platelet 
concentration. Our confocal microscopy studies of the morphology of the keratinocytes showed 
confluent layers of cells on all the platelet-containing samples. 
6.2.4 Fibroblasts seeded on the platelet-functionalized scaffolds 
The metabolic activity of fibroblasts seeded on platelet-functionalized samples is shown in 
Figure 20A. 
 
Figure 20 Fibroblast metabolic activity and proliferation. A – Metabolic activity of fibroblasts measured by MTS 
assay (statistical analysis p<0.05). B – Proliferation of fibroblasts determined by dsDNA fluorescence assay (statistical 
analysis p<0.05). The level of significance is denoted by the numbers above the bars in the graph, number 1 representing the 
P1 scaffold, 2 the P0.5 scaffold, 3 the P0.25 scaffold and 4 the PCL control scaffold193. 
Through the entire experiment the metabolic activity of fibroblasts on the P0.25 scaffold 
was significantly higher in comparison to the PCL scaffold. In addition to that, on day 1, 3 and 
7, the metabolic activity of fibroblasts seeded on the P0.25 scaffold was significantly higher 
than the metabolic activity of cells on scaffolds P1 and P0.5. From day 7, the metabolic activity 
of cells on the platelet-functionalized samples was significantly improved in comparison to the 
plain PCL control. On day 14, there were no statistically significant differences in the cell 
metabolic activity on the scaffolds functionalized with platelets. 
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Proliferation of fibroblasts (Figure 20B) was determined on day 1, 3, 7, and 14. There were 
no significant differences in the amount of the synthetized DNA between the samples with 
platelets and the PCL control until day 7 of the experiment. On day 7 and 14, there was a 
significantly larger amount of DNA on the scaffolds with platelets in comparison to the control 
PCL sample. There were no significant differences among the platelet-functionalized samples. 
Stimulation of fibroblast proliferation and ECM production in the presence of platelets was 
described by204. The positive effect of platelet-derived bioactive molecules on the 3T3 
fibroblasts observed in our study is in concordance with the results observed in a study focused 
on strategies for outcomes improvement in incisional hernia, where polypropylene (PP) mesh 
with or without PCL nanofibers coated with platelet-rich solution was evaluated191. Our study 
confirmed that the adhered platelets stimulated the cell metabolic activity and proliferation from 
day 1 of the experiment. It has been shown that during the first half of the experiment, the 
fibroblast responded the most in terms of proliferation and metabolic activity to the lowest 
concentration of platelets (sample P0.25). However, the differences among the platelet-
functionalized samples were levelled by the end of the experiment. 
Visualization of the fibroblasts can be seen in Fig. 5. On day 14, the fibroblast monolayers 
on samples containing platelets were almost confluent, in contrary to the control sample, where 
the increase in cell number was during the experiment only subtle. There were no significant 




Figure 21 Confocal images of fibroblasts seeded on the platelet-functionalized samples. Cellular membranes 
were stained by DiOC6(3) (green colour), cell nuclei using propidium iodide (red colour). A1 – P1 scaffold on day 1, A7 – P1 
scaffold on day 7, A14 – P1 scaffold on day 14, B1 – P0.5 scaffold on day 1, B7 – P0.5 scaffold on day 7, B14 – P0.5 
scaffold on day 14, C1 – P0.25 scaffold on day 1, C7 – P0.25 scaffold on day 7, C14 – P0.25 scaffold on day 14, D1 –PCL 
scaffold on day 1, D7 –PCL scaffold on day 7, D14 –PCL scaffold on day 14. A1, B1, C1, D1 – scale bar 100 μm, 
magnification 200x, A7, A14, B7, B14, C7, C14, D7, D14 – scale bar 100 μm, magnification 150×193. 
We have shown that the bioactive substances released from platelets stimulate both 
fibroblasts and keratinocytes. Interactions between keratinocytes and fibroblasts gradually shift 
the wound healing process from inflammation to the proliferative phase and granulation tissue 
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synthesis 33. Both cell types are essential to reduce the wound volume and to facilitate proper 
wound closure. Currently, there are very few drugs stimulating both cell types simultaneously 
and the development of such a system for deep wound healing would be very beneficial205. 
6.2.5 Melanocytes seeded on the platelet-functionalized scaffolds 
The metabolic activity of melanocytes seeded on the platelet-functionalized samples is 
shown in Figure 22A. 
 
Figure 22 Melanocyte metabolic activity and proliferation. A – Metabolic activity of melanocytes measured by MTS 
assay (statistical analysis p<0.05). B – Proliferation of melanocytes determined by dsDNA fluorescence assay (statistical 
analysis p<0.05). The level of significance is denoted by the numbers above the bars in the graph, number 1 representing the 
P1 scaffold, 2 the P0.5 scaffold, 3 the P0.25 scaffold and 4 the PCL control scaffold193. 
During the entire experiment the metabolic activity of melanocytes on the samples 
containing platelets was significantly higher in comparison to plain PCL. However, there were 
no statistically significant differences among the platelet-containing samples. 
The amount of synthetized DNA by melanocytes was determined as described above 
(Figure 22B). The data show the proliferation of melanocytes was increasing through the entire 
experiment. Platelets significantly promoted melanocyte proliferation on all the platelet-
functionalized scaffolds from day 7 in comparison to the PCL control. There were no significant 
differences among the platelet-functionalized samples in melanocyte proliferation. 
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The amount of melanin synthetized by melanocytes on the nanofibrous scaffolds (Figure 
23) was increasing throughout the entire experiment. 
 
Figure 23 Melanin synthesis on the platelet-functionalized scaffolds. The amount of the synthesized melanin was 
normalized to the amount of DNA contained on the scaffolds. The level of significance (p<0.05) is denoted by the numbers 
above the bars in the graph, number 1 representing the P1 scaffold, 2 the P0.5 scaffold, 3 the P0.25 scaffold and 4 the PCL 
control scaffold193. 
On day 7, there was a significantly larger amount of melanin on scaffold P1 containing the 
highest concentration of platelets in comparison to plain PCL nanofibers, indicating the higher 
concentration of the platelet-derived growth factors resulted in faster synthesis of melanin. 
However, on day 14, the amount of synthetized melanin was significantly larger on the P0.5 
scaffold in comparison to PCL control. The results suggest the lower concentrations of platelet-
derived molecules could result in more sustained melanin synthesis in the long-term. 
The Figure 24 shows melanocyte proliferation during the experiment. The observed 
increase in number of melanocytes seeded on the scaffolds with platelets between day 1 and 
day 7 was more pronounced in comparison to the PCL control. On day 7, the monolayers of 
the cells on the platelet-containing samples were almost confluent and no differences were 




Figure 24 Confocal images of melanocytes seeded on the platelet-functionalized samples. Cellular membranes 
were stained by DiOC6(3) (green colour), cell nuclei using propidium iodide (red colour). The black colour depicts the 
deposited melanin obtained by merge with images in visible light. A1 – P1 scaffold on day 1, A7 – P1 scaffold on day 7, A14 
– P1 scaffold on day 14, B1 – P0.5 scaffold on day 1, B7 – P0.5 scaffold on day 7, B14 – P0.5 scaffold on day 14, C1 – 
P0.25 scaffold on day 1, C7 – P0.25 scaffold on day 7, C14 – P0.25 scaffold on day 14, D1 –PCL scaffold on day 1, D7 –
PCL scaffold on day 7, D14 –PCL scaffold on day 14. A1, B1, C1, D1 – scale bar 100 μm, magnification 200x, A7, A14, B7, 
B14, C7, C14, D7, D14 – scale bar 100 μm, magnification 150×193. 
On the PCL control sample, the overall number of melanocytes was lower than on the 
platelet-functionalized samples and the cell monolayers were not confluent even by day 14 of 
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the experiment. In addition to that, the synthesized melanin was clearly visible on the scaffolds. 
In the confocal images merged with images in visible light, the melanin is depicted by the black 
colour. The absorption characteristics of melanin may interfere with the fluorescence-based cell 
proliferation assay, resulting in discrepancy of the results obtained via the proliferation assay 
and via confocal microscopy. 
Melanocytes are cells responsible for proper pigmentation of the skin. The lack of 
pigmentation (and thus UV protection) is a common issue in tissue-engineered skin 
substitutes53,54. Furthermore, there are several pigmentation disorders with vitiligo being the 
most common, characterized by white lesions due to the loss of functional melanocytes206. The 
concept of a cellular patch has been proposed for vitiligo therapy207. Using a suitable 
biomaterial, healthy melanocytes are expanded. The biomaterial further provides the cells with 
mechanical support during the transplantation to the site of lesion. As such material, several 
polymers in the form of films have been studied (polylactic acid, polyvinyl chloride and silicone 
or chitosan coated polystyrene207–209). Some of the materials have been used in clinical 
practice, for example polylactic acid or human amniotic membrane210,211. We have shown the 
PCL nanofibers are suitable biomaterial for melanocyte culture. These results were further 
supported by a study evaluating PCL nanofibres for culture and differentiation of melanocytes 
isolated from the outer root sheath of a hair follicle, suggesting the suitability of PCL nanofibres 
for split-thickness epidermal models212. Furthermore, the functionalization of nanofibers with 
platelets led to a significant increase in cell proliferation, metabolic activity and melanin 
synthesis. According to the confocal microscopy images, the colonization of the scaffolds by 
melanocytes was extremely effective. 
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The results of the study showed that the system was able to stimulate fibroblasts, 
keratinocytes and melanocytes and could serve as a viable system for tissue engineering. It 
combines the mechanical stability of PCL nanofibers with the bioactive action of platelets. Our 
proposed system could serve as a cell-free scaffold that promotes fibroblast and keratinocyte 
proliferation, migration and angiogenesis via VEGF released from the adhered platelets195,213. 
The stimulation of keratinocyte and fibroblast growth on scaffolds should foster the healing 
process and may decrease the healing times as a crucial complication in chronic wounds. 
Additionally, the melanocytes could improve pigmentation outcomes of skin substitutes or the 
system could serve as a scaffolding system for melanocyte transplantation in vitiligo therapy. 
No significant concentration-dependent effect of the platelets was found, thus even the 
lowest tested concentration was able to stimulate the skin cells. In addition, the simple adhesion 
method enables fast and convenient on-site preparation and rapid translation to clinical 
practice. 
6.2.6 Summary 
The aim of the sub-study was to develop a simple drug delivery system that would prolong 
the presence of bioactive molecules with short half-time at the site of delivery. The results of 
the study showed that the morphology of the PCL nanofibres promoted platelet activation and 
resulted in formation of a thick fibrin network. The median half-time of EGF release was 1.7 
days. The metabolic activity and proliferation of keratinocytes was improved on the platelet-
functionalized PCL samples in a dose-dependent manner. In contrary, the best metabolic 
activity and proliferation of fibroblasts was achieved on the PCL sample containing the lowest 
tested platelet concentration, which was in accordance with our previous platelet lysate study. 
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Furthermore, the metabolic activity of melanocytes seeded on the platelet-functionalized 
samples was significantly stimulated regardless the platelet concentration. Therefore, even the 
lowest tested platelet concentration was able to achieve comparable results as the highest 
tested platelet concentration. Similarly, the presence of platelets resulted in stimulation of 
melanin synthesis. 
6.3 Comparison of PCL scaffolds functionalized with native platelets 
To compare the efficacy of platelet adhesion to the surface of nanofibres prepared by 
different fibre-fabricating techniques, PCL meshes were prepared using electrospinning (ES) 
and centrifugal spinning (CS). The scaffolds were functionalized with native human leucocyte-
poor buffy coat-derived platelets at varying concentrations. The effect of the released platelet-
derived molecules was investigated using murine melanocytes melan-a. The composition of 




Table 8 Composition of the electrospun and centrifugal samples functionalized with platelets in the Experiment 6.3. 
 Sample Platelet concentration 
Electrospun scaffolds   
10x physiological concentration E10PC 3,000x109 platelets/L 
3x physiological concentration E3PC 900x109 platelets/L 
Physiological concentration EPC 300x109 platelets/L 
3x diluted physiological concentration E0.3PC 100x109 platelets/L 
10x diluted physiological concentration E0.3PC 30x109 platelets/L 
Centrifugal spun scaffolds   
10x physiological concentration C10PC 3,000x109 platelets/L 
3x physiological concentration C3PC 900x109 platelets/L 
Physiological concentration CPC 300x109 platelets/L 
3x diluted physiological concentration C0.3PC 100x109 platelets/L 
10x diluted physiological concentration C0.1PC 30x109 platelets/L 
 
6.3.1 Characterization of the scaffold 
Nano-/microfibrous scaffolds were prepared using the two fibre-forming techniques; 
electrospinning and centrifugal spinning. Generally, both types of scaffolds mimic the native 
ECM thanks to their porosity, pore interconnection and fibrous structure. However, the 
electrospun fibrous layer is more planar, forming rather a 2D-like structure in comparison to the 
centrifugal spun 3D-like scaffolds. The morphology of the layers was in accordance. In the 
electrospun samples, the mean fibre diameter was found to be 581 ± 522 nm. The fibre 
diameter of the dominant nanofibrous fraction was 203 nm. The diameter of the less 
represented microfibrous fraction was up to 2,500 nm. The morphology of the electrospun mesh 
was more compact, with a mean pore size of 1.5 ± 2 µm2 and a maximum pore size of 37.2 µm2. 
The porosity of electrospun fibres was 55.0 ± 4.2%. The mean fibre diameter in the centrifugal 
spun samples was 701 ± 494 nm, with the maximum fibre diameter of 2,785 nm and the 
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minimum fibre diameter of 126 nm. However, the pore size was distinctly improved to 
15.2 ± 22.7 µm2, with a maximum pore size of 239 µm2. The porosity of the centrifugal spun 
fibres, 64.6 ± 3.25%, was significantly improved in comparison to the electrospun samples. It 
has been shown that the more open morphology of the centrifugal spun samples fosters cell 
penetration into the deeper layers of the scaffold214. 
 
Figure 25 Scanning electron microscopy of the electrospun and centrifugal spun PCL nanofibrous samples 
with adhered platelets. The images acquired on day 1 illustrate the fibrin network formed on the surface of the two samples 
with the highest platelet concentrations (E10PC, C10PC, E3PC, and C3PC) and the electrospun (EPCL) and centrifugal 
spun (CPCL) control samples. Magnification 6,000x; scale bar 10 µm. 
The platelets adhered to the surface of the nanofibres were visualized using SEM (Figure 
25). The acquired images showed clear fibrin network formed on the two highest concentrations 
of the electrospun and centrifugal spun scaffolds (samples E10PC, C10PC, E3PC and C3PC). 
On the samples with the lower platelet concentrations, the fibrin network was very scarce. The 
presence of the fibrin network was decreasing with the decreasing platelet concentration, and 
on the samples E0.1PC and C0.1PC, no fibrin network was detected. 
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On the centrifugal spun samples, there were more platelets embedded within the fibrin 
network. The platelets showed morphology typical for their activated state. Another study that 
used centrifugal spun PCL nanofibers with adhered platelets for stimulation of proliferation and 
viability of MG-63 cells, showed, that platelets of circular shape were present on the surface of 
the nanofibres even after 14 days215. 
The viability of platelets adsorbed to the surface of nanofibers was determined using the 
MTS assay on days 1, 3, 7 and 14 (Figure 26). 
 
Figure 26 Viability of platelets seeded on the electrospun and centrifugal spun PCL scaffolds. The viability of 
platelets was determined using and MTS assay. A – Viability of platelets seeded on the electrospun scaffolds. B – Viability of 
platelets seeded on the centrifugal spun scaffolds. 
The viability of the highest concentration of platelets seeded on the centrifugal spun 
scaffolds (C10PC) was almost 2 times higher in comparison to the corresponding electrospun 
scaffolds (E10PC) on day 1, indicating adsorption of more platelets to the centrifugal spun 
scaffolds. Otherwise, the metabolic activity of the adsorbed platelets on the electrospun and 
centrifugal scaffolds was almost negligible throughout the experiment. 
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6.3.2 Characterization of the platelets 
The concentrations of bioactive molecules contained in the platelets were determined using 
the X-MAP technology. The summary of the obtained results is shown in Table 9.Table 9 




Table 9 Concentration of the determined analytes in the platelet concentrate. 
Pro-inflammatory cytokines 
 IL-1b 1.6 ± 0.1 pg/mL 
 IL-2 7.7 ± 0.4 pg/mL 
 IL-6 15.6 ± 3.5 pg/mL 
 IL-7 14.8 ± 0.9 pg/mL 
 IL-8 19.2 ± 1.1 pg/mL 
 IL-9 95.4 ± 2.7 pg/mL 
 IL-12 <LOQ 
 IL-15 239.7 ± 15.1 pg/mL 
 IL-17 17.7 ± 1.0 pg/mL 
 IFN-γ 9.1 ± 0.4 pg/mL 
 TNF-α 57.2 ± 3.0 pg/mL 
Anti-inflammatory cytokines 
 IL-1ra 214 ± 11.3 pg/mL 
 IL-4 1.2 ± 0.1 pg/mL 
 IL-5 41.2 ± 2.8 pg/mL 
 IL-10 <LOQ 
 IL-13 <LOQ 
Chemokines 
 Eotaxin 23.3 ± 0.7 pg/mL 
 IP-10 225.0 ± 4.6 pg/mL 
 MCP-1 12.3 ± 1.1 pg/mL 
 MIP-1a 1.3 ± 0.1 pg/mL 
 MIP-1b 1,427.1 ± 91.1 pg/mL 
 RANTES 16,082.4 ± 1,498 pg/mL 
Growth factors 
 IGF-1 32.4 ng/mL 
 TGF-β1 17,569.9 ± 1,507.8 pg/mL 
 bFGF 67.6 ± 4.1 pg/mL 
 G-CSF 79.0 ± 5.9 pg/mL 
 GM-CSF 6.5 ± 0.4 pg/mL 
 PDGF-BB 1,125.8 ± 48.1 pg/mL 




The concentrations of the measured analytes corresponded to the values observed in our 
other studies215 and to the values observed by other groups118,178. 
6.3.3 Release characteristics of the bioactive molecules 
To characterize the release of bioactive molecules from the functionalized samples, levels 
of thrombospondin-1 and TGF-β1 released from the electrospun and centrifugal spun scaffolds 
were detected. TSP-1 is a bioactive molecule abundant in the platelet, fostering the proliferative 
processes during wound healing. The obtained data for TSP-1 are shown as cumulative (Figure 
27A) and relative (Figure 27B) release. 
Detectable amounts of thrombospondin were present only in the samples with the three 
highest concentrations of TSP-1 (10-fold physiological concentration of platelets E10PC and 
C10PC, 3-fold physiological concentration of platelets E3PC and C3PC, and physiological 
concentration of platelets EPC and CPC). The cumulative release of TSP-1 (Figure 27A) 
showed that the adhesion of platelets to the centrifugal spun scaffolds resulted in an 
approximately two-fold increase of the TSP-1 amount when compared to the electrospun 
scaffolds. In the centrifugal spun sample with the highest concentration of platelet (C10PC), a 
significant amount of TSP-1 was detected even on day 14. On the contrary, all the TSP-1 was 




Figure 27 Cumulative and relative release of thrombospondin-1 from the platelet functionalized electrospun and 
centrifugal spun samples. Data for the samples with the three highest concentrations (E/C 10PC, 3PC, and PC) are shown; 
the lower concentrations were below the detection limit of the assay. A – Cumulative release of TSP-1 from the electrospun 
(E10PC, E3PC, EPC) and centrifugal spun (C10PC, C3PC, CPC) samples. B – Relative release of TSP-1 from the electrospun 
and centrifugal spun samples. The release characteristics of the CPC, E3PC and EPC samples were identical, therefore, they 
overlap in the graph. C – Relative release of TSP-1 from the centrifugal spun samples. D – Relative release of TSP-1 from the 
electrospun samples; the release characteristics of the E3PC and EPC samples were identical. 
Furthermore, the release of TGF-β1 from the platelet-functionalized scaffolds was 




Figure 28 Cumulative and relative release of TGF-β1 from the platelet functionalized electrospun and centrifugal 
spun samples. Data for the samples with the four highest concentrations (E10PC, E3PC, EPC, E0.3PC, C10PC, C3PC, CPC, 
and C0.3PC) are shown; the lower concentrations were below the detection limit of the assay. A – Cumulative release of TGF-
β1 from the electrospun (E10PC, E3PC, EPC, and E0.3PC) and centrifugal spun (C10PC, C3PC, CPC, and C0.3PC) samples. 
B – Relative release of TGF-β1 from the electrospun and centrifugal spun samples. The release characteristics of the CPC, 
E3PC and EPC samples were identical, therefore, they overlap in the graph. C – Relative release of TGF-β1 from the centrifugal 
spun samples. D – Relative release of TGF-β1 from the electrospun samples; the release characteristics of the E3PC and EPC 
samples were identical. 
The Figure 28A shows cumulative release of TGF-β1. The data followed similar trend when 
compared to the TSP-1 data. There was significantly higher concentration of detected TGF-β1 
on the centrifugal spun scaffolds when compared to the respective electrospun scaffolds, 




The relative release characteristics revealed that the release of TSP-1 and TGF-β1 was 
faster when compared to the release of EGF in the Experiment 6.2. The half-time release of 
TSP-1 from the platelet-functionalized samples ranged from 0.5 days to almost 1 day and is 
shown in Table 10. 
Table 10 Half-time of TSP-1 and TGF-β1 release from the platelet-functionalized samples. The table represents 
the time to release of 50% of the contained TSP-1 and TGF-β1 in days. 
Sample Half-time of TSP-1 release (days) Half-time of TGF-β1 release (days) 
C10PC 0.98 1.46 
C3PC 0.59 1.11 
CPC 0.5 0.96 
E10PC 0.57 1.19 
E3PC 0.5 0.86 
EPC 0.5 0.63 
 
The half-time of release of TGF-β1 (Table 10) was longer when compared with the detected 
levels of TSP-1, and the half-time decreased with the decreasing platelet concentration. These 
findings indicated stronger interaction of TGF-β1 with the fibrin matrix formed on the surface of 
the nanofibres. This is in accordance with the findings of a study that investigated binding of 
several growth factors (TGF-β1 included). In the study, the growth factors were combined with 
fibrinogen solution; the fibrinogen was polymerized using thrombin and factor XIII. The 
concentration of growth factors released from the fibrin matrix was determined. The study 
showed strong interaction of TGF-β1 with fibrinogen via its heparin-binding domain. In the 




6.3.4 Melanocytes seeded on the platelet-functionalized samples 
To test the biocompatibility of the scaffolds, the metabolic activity melanocytes seeded on 
platelet-functionalized scaffolds was determined. The metabolic activity of the melanocytes is 
shown in the Figure 29. The Figure 29A shows the metabolic activity of melanocytes seeded 
on the electrospun scaffolds and the Figure 29B shows the metabolic activity of melanocytes 
seeded on the centrifugal spun scaffolds. The acquired data showed a clear tendency of a 
dose-dependent effect of the platelet concentration adsorbed to the scaffolds. On the 
electrospun scaffolds, the bioactive compounds released from the platelets significantly 
improved the melanocyte metabolic activity in comparison to the plain PCL control from day 3 
of the experiment. By the end of the experiment, the three highest platelet concentrations 
(samples EPC10, EPC3, and EPC) significantly improved melanocyte metabolic activity in 
comparison to the below-physiologic platelet concentration, with the sample EPC3 showing the 
highest metabolic activity. Furthermore, even the below-physiologic platelet concentrations 
(E.03PC and E0.1PC) resulted in improved melanocyte metabolic activity when compared to 
the PCL control. 
 
Figure 29 Metabolic activity of melanocytes seeded on the electrospun and centrifugal spun scaffolds. A – 
Metabolic activity of melanocytes seeded on the electrospun PCL scaffolds measured by MTS assay (statistical analysis 
p<0.05). B – Metabolic activity of melanocytes seeded on the centrifugal spun PCL scaffolds measured by MTS assay 
(statistical analysis p<0.05). The level of significance is denoted by the numbers above the bars in the graph. ES stands for 
electrospun, CS stands for centrifugal spun. 
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The metabolic activity of melanocytes seeded on the centrifugal spun scaffolds is shown in 
the Figure 29B. Similarly, as in the case of the electrospun scaffolds, the metabolic activity of 
melanocytes seeded on the centrifugal spun scaffolds was platelet concentration-dependent. 
In contrary to the below-physiological platelet concentrations (C0.1PC and C0.3PC), the 
melanocyte metabolic activity was significantly improved in comparison to the PCL control from 
day 3. By the end of the experiment, the highest melanocyte metabolic activity was detected 
on the scaffold with the highest platelet concentration (C10PC), followed by the second highest 
concentration (C3PC) and the physiological platelet concentration (CPC). 
The overall statistical analysis of the all obtained data (data not shown in the graphs) 
showed there were no statistically significant differences between the electrospun and 
centrifugal spun samples on day 1, 3, and 7. However, on day 14, the metabolic activity of 
melanocytes seeded on the C10PC scaffolds (centrifugal spun scaffolds seeded with the 
highest tested platelet concentration) was significantly improved not only in comparison to all 
the other tested centrifugal spun scaffolds, but in comparison to the all tested electrospun 
scaffolds as well. Furthermore, even the metabolic activity of melanocytes seeded on the 
second highest tested concentration of platelets adhered to the centrifugal scaffold (C3PC) was 
significantly improved in comparison to all the tested electrospun samples. These differences 
were levelled out at the physiological platelet concentration, as there was no significant 
difference in the metabolic activity of melanocytes seeded on the CPC and EPC samples. 
Furthermore, the morphology of the electrospun and centrifugal spun nanofibrous samples did 
not seem to affect the melanocyte metabolic activity, as there were no significant differences 
detected on the plain PCL controls. 
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A similar trend was observed in the melanocyte proliferation data shown in Figure 30. The 
Figure 30A shows proliferation of melanocytes seeded on the electrospun scaffolds, the Figure 
30B shows proliferation of melanocytes seeded on the centrifugal spun scaffolds. 
 
Figure 30 Proliferation of melanocytes seeded on the electrospun and centrifugal spun scaffolds. A – 
Proliferation of melanocytes seeded on the electrospun PCL scaffolds (statistical analysis p<0.05). B – Proliferation of 
melanocytes seeded on the centrifugal spun PCL scaffolds (statistical analysis p<0.05). The level of significance is denoted 
by the numbers above the bars in the graph. ES stands for electrospun, CS stands for centrifugal spun. 
There were only mild statistically significant differences in proliferation of melanocytes 
seeded on the electrospun scaffolds, with the E3PC scaffold achieving the highest proliferation 
on day 7 of the experiment. Furthermore, the scaffolds with the three highest platelet 
concentrations (E10PC, E3PC, and EPC) reached a significantly improved proliferation in 
comparison to the plain PCL control on day 14. The differences in melanocyte proliferation were 
more pronounced on the centrifugal spun samples. In the first half of the experiment, there were 
no statistically significant differences in melanocyte proliferation. However, on day 7, the 
proliferation of melanocytes seeded on the centrifugal spun scaffolds with the highest platelet 
concentration (C10PC) was significant higher when compared to the all other centrifugal spun 
scaffolds, followed in the trend by the second highest platelet concentration (C3PC). The same 
trend was observed on day 14 of the experiment. The melanocyte proliferation on samples 
CPC and C0.3PC was improved compared to the plain PCL control. However, on the sample 
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functionalized with the lowest platelet concentration (C0.1PC), no improvement in melanocyte 
proliferation was achieved. The overall statistical analysis (data not shown in the graphs) 
confirmed the trend observed in the metabolic activity data. On day 7, the metabolic activity of 
melanocytes seeded on the centrifugal spun C10PC scaffold showed the highest proliferation 
when compared to all the centrifugal spun and electrospun scaffolds as well. Furthermore, the 
response was observed on day 14 as well, when the C10PC and the C3PC samples showed a 
superior proliferation when compared to all the electrospun samples (in addition to the 
centrifugal spun samples). Similarly, there was no difference in proliferation of melanocytes 
seeded on the plain electrospun or centrifugal spun PCL control, suggesting the sole effect of 





Figure 31 Confocal images of melanocytes seeded on the platelet-functionalized electrospun or centrifugal 
spun samples. Cellular membranes were stained by DiOC6(3) (green colour), cell nuclei using propidium iodide (red 
colour). For each sample, a representative image from day 7 and day 14 is given. Magnification 200x, scale bar 50 µm. 
The morphology of melanocytes seeded on the platelet-functionalized samples was 
visualized using confocal microscopy (Figure 31). The confocal microscopy images confirmed 
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the other obtained data. A significant increase in cell number was observed from day 7 to day 
14 on the electrospun and the centrifugal spun nanofibrous scaffolds. There was an obvious 
difference in cell numbers on the platelet-functionalized samples and on the PCL control, on 
both the electrospun and the centrifugal spun scaffolds. Furthermore, the melanocytes cultured 
on the centrifugal spun scaffolds showed more dendritic morphology and formed a more 
complex network in comparison to the melanocytes cultured on the more 2D-like electrospun 
morphology. Similar changes in melanocyte morphology in a platelet lysate-enriched culture 
medium were observed172. These changes may be attributed to the high PDGF-BB contained 
in the platelets, as the PDGF-BB has been shown to stimulate melanogenesis, dendritogenesis, 
and differentiation of human melanocytes217. 
6.3.5 Summary 
The results of the study showed that surface and more porous structure of the centrifugal 
spun scaffolds resulted in an almost 2-fold increase in the number of platelets adhered to the 
surface of the fibrous mesh. Furthermore, the fibrin network formed on top of the nanofibres 
served as a drug delivery system, slowing down the release of TGF-β1 in comparison to the 
TSP-1. The biological activity of the system was tested using melanocytes. The obtained data 
showed a strong dose-dependent behaviour of melanocytes seeded on the platelet-
functionalized scaffolds. Furthermore, no significant effect of the morphology of the 2D-like 
electrospun scaffold and 3D-like centrifugal spun scaffold was shown, however, based on the 




6.4 Comparison of platelet lyophilizate-loaded scaffolds 
As systems containing native platelets have rather short-term lifespan, the aim of the study 
was to develop a system delivering platelet-derived growth factors in a long-term manner. The 
nanofibrous scaffolds were prepared by needleless electrospinning and centrifugal spinning 
technique. The aim of the study was to compare two coaxial fibre formation techniques. Platelet 
lyophilizate was embedded into the coaxial nanofibres as a natural source of growth factors 
and cytokines, the precise composition of the samples is given in Table 2. The effect of differing 
stereology of the electrospun and centrifugal spun scaffolds, as well as of the released platelet-
derived molecules, was investigated using murine keratinocytes XB2 and fibroblasts 3T3-A31. 
6.4.1 Characterization of the fibrous scaffolds 
Proper choice of scaffold is one of the major factors influencing the repair of a tissue 
function. Stereological measurements of the prepared electrospun and centrifugal spun 
nanofibrous layers showed morphology typical for PCL (Figure 32). The electrospun layer 
consisted of a population of nano- and microfibers with a minimum of non-fibrous defects. The 
mean diameter of the thin nanofibrous fraction was 384 ± 196 nm. Furthermore, a fraction of 




Figure 32 Scanning electron microscopy of the electrospun (ES) and centrifugal spun (CS) PCL nanofibrous 
samples. Electrospun samples containing 1% PF-68, 5% PF-68 and 10% PF-68 (ES1, ES5 and ES10, respectively); 
magnification 2,000x and scale bar 20 µm. Centrifugal spun samples 1% PF-68, 5% PF-68 and 10% PF-68 (CS1, CS5 and 
CS10, respectively); magnification 650x and scale bar 50 µm218. 
According to the stereological measurements of the centrifugal spun layers, the samples 
contained thicker microfibres with a mean diameter of 1,390 ± 626 nm. The measurement of 
the pore size of the prepared fibrous mats showed a statistically significant increase in the pore 
size in all the centrifugal spun samples when compared to the electrospun samples. The 
median pore size of the electrospun samples ranged from 2.5–2.8 μm2 and of the centrifugal 
samples 4.2–5.8 μm2. The electrospun samples contained 0 to 22 % of pores larger than 4 




Figure 33 Pore size of the fabricated fibrous scaffolds. The pore sizes measured in the fabricated electrospun and 
centrifugal spun core-shell scaffolds. ES PCL-1% PF-68 (ES1), ES PCL-5% PF-68 (ES5), ES PCL-10% PF-68 (ES10), CS 
PCL-1% PF-68 (CS1), CS PCL-5% PF-68 (CS5), CS PCL-10% PF-68 (CS10). The data are presented in box plots with 
whiskers. ♦ denotes the minimum, ■ denotes the maximum and □ denotes the mean value218. 
The morphology of the electrospun scaffolds was shown to promote keratinocyte, 
melanocyte and fibroblast growth172,191. The nanofibres in the microfibrous network supported 
cell adhesion. Pham et al. described higher cellular spreading on nanofibrous scaffolds with 
when compared to microfibrous layers219. The structure of the electrospun scaffolds was rather 
planar with a tightly packed fibre network. The sheet-like structure of the electrospun scaffolds 
did not allow cell penetration through the scaffold, and the cells were growing in the superficial 
50 μm of the scaffold214,219,220. The planar structure may be favourable for skin tissue 
engineering applications. The nanofibrous sheet acts as a barrier-like scaffold. The seeded 
cells are localised on the basal part of the wound and the scaffold protects them from the outer 
environment. In contrast to that, the centrifugal spun scaffolds are more 3D structures. This 
was caused mainly by to the dominant presence of microfibres. The fibres were more loosely 
organized, and the mean pore size was significantly larger. The scaffolds showed a median 
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pore size ranging from 4.2 to 5.8 μm2, with dominant presence of pores larger than 4 μm2. The 
common migration protocols for fibroblasts used an 8 μm pore size for migration testing 221. 
Furthermore, the mean pore size for cell penetration in vivo was much smaller than the 
predicted in vitro value. This could relate to individual fibres pushing apart during cell 
movement222. Our previous study showed improved penetration of cells through the PCL 
scaffolds prepared by centrifugal spinning compared to electrospinning91,214. 
The scaffolds were enriched by platelet-derived bioactive molecules to stimulate cell 
proliferation. The presence of the PF-68 core micelles containing the platelet lyophilizate 
proteins in the fibrous meshes was confirmed by FTIR-ATR spectroscopy. The control PCL 
fibres showed a typical FTIR spectra with a dominant C=O stretch band at 1,750 cm-1 and a 
typical fingerprinting zone. The control PF-68 sample showed strong absorption in 2,750–3,000 
cm-1, corresponding to the resonance of C-H groups and resonance in 3,500 cm-1 region 
corresponding to the O-H stretch. In the case of both electrospun and centrifugal spun PCL-
PF-68 nanofibres with the PF-68 as a core phase, the band corresponding to the O-H stretch 
band at 3,200–3,600 cm-1 was present. The band has a broad shape and the absorbance 




Figure 34 FTIR-ATR spectra of electrospun and centrifugal spun PCL and PCL-PF-68 nanofibres. Spectra of PCL, 
PF-68, ES PCL-1% PF-68 (ES1), CS PCL-1% PF-68 (CS1), ES PCL-5% PF-68 (ES5), CS PCL-5% PF-68 (CS5), ES PCL-
10% PF-68 (ES10), CS PCL-10% PF-68 (CS10). The difference in spectra indicate the resonance of PF-68 groups at 3200-
3600 cm-1 (O-H stretch), 2775-3000 cm-1 (C-H stretch) and 1600 cm-1 (C-N stretch)218. 
In the case of both electrospun and centrifugal spun samples containing core of 10% PF-
68, an increased C-H stretch peak (2,850–3,000 cm-1) was observed. The change in spectra 
was in accordance with the PF-68 composition consisting of polyethylene oxide and 
polypropylene oxide units. Nevertheless, the presence of the platelet lyophilizate resulted in an 
increased absorbance at 1,600 cm-1 corresponding to a C-N stretch of proteins in all samples 
containing the platelet lyophilizate. 
6.4.2 Characterization of the platelet lyophilizate 
The total protein content in the platelet lyophilizate was determined to be 0.48 mg/mL. The 
BioPlex multiplex assay was performed to assay the concentrations of specific mediators 




Figure 35 Concentration of the assayed mediators in the platelet lyophilizate218. 
According to the obtained data, the lyophilizate contained various pro- and anti-
inflammatory mediators; the most abundant pro-inflammatory mediator was IL-17. Furthermore, 
chemokines and growth factors were found in the platelet lyophilizate, which are of great 
importance in tissue engineering applications. The most represented chemokine and growth 
factor were RANTES and PDGF-BB, respectively.  
Comparable levels of cytokines, chemokines and growth factors were detected by the 
XMAP assay in platelet lyophilizate encapsulated into centrifugal spun nanofibres, native 
platelets adhered to the surface of centrifugal spun PCL nanofibers and the platelet lysate used 
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in cell culture in the Experiment 6.1 (Buzgo et al. 2017; Rampichova et al. 2017). The data 
demonstrated the preservation of the growth factors during the freeze-drying process of the 
platelets. Such preparation provides a significant improvement in shelf-life. It is possible to keep 
the freeze/dried platelets functional for up to two years223. Additionally, by lyophilization of the 
platelets, their loading into nanofibres in the powder form is facilitated during the fabrication 
processes. The concentration of the platelet lyophilizate in the solutions used for spinning can 
be tailored to the requirements of the particular application, and, furthermore, the lyophilizate 
is soluble in suitable solvents. 
6.4.3 Release characteristics of the bioactive molecules 
The release profiles of platelet lyophilizate encapsulated into the core-shell electrospun 
and centrifugal spun nanofibres were determined and are shown in Figure 36. The Figure 36A, 
illustrating the cumulative release, shows the dependence of the absolute amount of the 
bioactive molecules contained in the platelet lyophilizate on the concentration of the core 
polymer PF-68 (1 to 10%), whereas the Figure 36B, illustrating the relative release, shows the 
release rate of the bioactive molecules and its dependence on the PF-68 core concentration. 
The data obtained during measuring the relative total protein release from the electrospun and 
centrifugal spun samples, the embedded proteins were released in a higher rate (a burst) during 




Figure 36 Total protein release from the electrospun and centrifugal spun fibrous scaffolds. A – Cumulative total 
protein release, B – Relative total protein release. ES PCL-1% PF-68 (ES1), CS PCL-1% PF-68 (CS1), ES PCL-5% PF-68 
(ES5), CS PCL-5% PF-68 (CS5), ES PCL-10% PF-68 (ES10), CS PCL-10% PF-68 (CS10). Lines in black colour represent 
the protein release from the electrospun scaffolds, lines in grey colour represent the centrifugal spun scaffolds. 
The amount of the protein released on day 1 ranged from 20 to 24 percent in all the tested 
samples. The burst release was followed by a sustained release continuing for 30 days. In 
electrospun fibres, the release rate increased with increasing PF-68 core concentration. The 
half-time of release for the ES1 sample (1% PF-68 fibres) was determined to be 10.4 days. In 
the case of the higher core concentrations, the release was faster and half-time was shifted to 
5.3 days for ES5 (5% PF-68) and 4.2 days for ES10 (10% PF-68). Similar pattern was followed 
by the centrifugal spun scaffolds; the half-time of the release was decreasing with the increasing 
PF-68 concentration. In the case of the sample CS1 (1% PF-68), it was 6.5 days and in CS5 
(5% PF-68) and CS10 (10% PF-68) it decreased to 4 and 3.6 days, respectively. The faster 
release from the samples correlates with the behaviour observed in our previous studies. The 
emulsion electrospinning prepares fibres for long-term delivery of active molecules 98. In the 
case of centrifugal spinning, the fibres showed a similar release pattern and the mean release 
time was shorter than in the studies with electrospun fibres91,224–226. This may be caused by 
better encapsulation of molecules and more homogenous core droplet distribution in 
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electrospun fibres. In centrifugal spun fibres due to high centrifugal forces, the droplets are 
shifted closer to the surface of the fibres resulting in faster release. 
The highest total protein release (Figure 36A) was detected in the groups containing 10% 
PF-68 as a core phase, for both electrospun and centrifugal spun fibres. With a decreasing PF-
68 concentration, the amount of the released proteins decreased and was lowest for the 
samples containing 1% PF-68. The higher total cumulative release of protein in samples with a 
higher PF-68 concentration may relate to the higher presence of PF-68 core micelles in the 
structure of the fibre. This hypothesis is confirmed by the higher number of PF-68 core droplets 
observed during the emulsion centrifugal spinning process91. The higher number of core 
droplets results in a higher droplet interconnection and a lower number of the isolated droplets, 
forming a more continuous core in the core/shell-like structure. Upon interaction of fibres with 
high PF-68 concentration with an aqueous solvent, the water diffuses into these droplet pores 
and dissolves the core droplets, resulting in a higher and faster release. The droplet 
interconnection enables further diffusion and desorption from deeper droplets without the need 
for fibre degradation. In the case of scaffolds with a lower PF-68 concentration, the number of 
interconnected droplets available for release is lower, resulting in a more sustained, yet less 
intensive release. A long-term release is in the case of fibres driven both by diffusion and 
degradation mechanisms227. The PCL fibre degradation is slow and plays a less dominant 
role228. The surface degradation of the fibres was observed on the SEM images taken on day 




Figure 37 Scanning electron images showing the degradation of the electrospun and centrifugal spun 
scaffolds. The SEM images were taken after 1 and 17 days of incubation in an aqueous solution. Control scaffolds and 
scaffolds containing 10% PF-68 (ES10 and CS10) were used to illustrate the changes. After the 17-day immersion of the 
scaffolds in the aqueous solution, the scaffolds were fixed using glutaraldehyde and dehydrated. On day 17, degradation 
changes of the surface of the fibres were observed. Magnification 8000x, scale bar 5 µm218. 
After a short-term (1-day) incubation in the aqueous solvent, the samples showed smooth 
surface indicating tight polymer chain interconnection. On the other hand, after 17 days of 
incubation, the changes in fibre surface morphology were apparent. The fibres showed more 
structured surface connected with changes in polymer chain organization. Such changes 
resulted in more porous structure of the fibres and may play role in release from the scaffolds. 
Besides erosion of the fibre surface, the release is regulated by the rate of drug and water 
diffusion. The diffusion is driven via the interconnected droplets and through nanopores in the 
PCL fibre structure, observed previously84. The hypothesis correlates both with the release half-
times and the amount of the total protein released from our scaffolds. 
The molecular mechanisms behind wound healing highlight the suitability of platelets as a 
source of growth factors. The release from the fibres correlates with the time frame of skin 
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regeneration. The cytokines contained in platelets stimulate the healing processes, and after 
their incorporation into the fibrous meshes, the scaffolds stimulate progress through the wound 
healing phases. The pattern of the protein release from our scaffolds correlates with the 
duration of the wound healing phases. The half-time of release from 3 to 5 days for samples 
with 5% and 10% PF-68 provides an optimal stimulation for the early and middle phases of 
wound healing. Nevertheless, the prolonged release enables the extension of wound dressing 
exchange intervals and helps to decrease the economic burden related to the successful 
healing of wounds. 
6.4.4 Fibroblasts seeded on the fibrous scaffolds 
The platelet lyophilizate embedded into the scaffolds was used for stimulation of fibroblast 
proliferation and their metabolic activity (Figure 38). The biocompatibility of the fibrous meshes 
was tested using 3T3 fibroblasts. The metabolic activity of the seeded fibroblasts was evaluated 
using the MTS assay on days 1, 3, 7, 14 and 17. The data showed similar results for stimulation 
of metabolic activity of the seeded fibroblasts on the electrospun (Figure 38A) and centrifugal 
spun scaffolds (Figure 38B). In both the electrospun and centrifugal spun samples, the samples 
containing the highest amount of the platelet lyophilizate (ES10 or CS10) were superior in terms 
of stimulation of fibroblast metabolic activity. Furthermore, the performed overall statistical 
analysis of all the acquired data confirmed, that the metabolic activity of the seeded fibroblasts 
on the centrifugal spun sample CS10 (highest loading capacity) was significantly higher in 
comparison to all the tested samples (electrospun and centrifugal spun) on day 14 and higher 




Figure 38 Metabolic activity and proliferation of fibroblasts seeded on the electrospun and centrifugal spun 
scaffolds. A – Metabolic activity of fibroblasts seeded on the electrospun scaffolds, B – Metabolic activity of fibroblasts seeded 
on the centrifugal spun scaffolds, C – Proliferation of fibroblasts seeded on the electrospun scaffolds, D – Proliferation of 
fibroblasts seeded on the centrifugal spun scaffolds. ES PCL-1% PF-68 (ES1), ES PCL-5% PF-68 (ES5), ES PCL-10% PF-68 
(ES10), ES PCL Control, CS PCL-1% PF-68 (CS1), CS PCL-5% PF-68 (CS5), CS PCL-10% PF-68 (CS10), CS PCL Control. 
D1 – D17 denote experimental days. The level of significance is denoted by the numbers above the bars in the graph, number 
1 representing the E/CS1 scaffold, 2 the E/CS5 scaffold, 3 the E/CS10 scaffold and 4 the E/CS control scaffold Statistical 
significance was set at p<0.05218. 
The proliferation data for the days corresponding to the MTS assay showed a similar 
pattern (Figure 38C-D). The statistical analysis of all samples showed a significantly improved 
initial adhesion of fibroblasts to all the centrifugal spun samples on day 1 when compared to 
the electrospun samples. Such trend was maintained until day 14 of the experiment. On day 
14, all the differences between the centrifugal spun and electrospun samples were levelled out. 
The samples with the highest loading capacity (ES10, CS10) yielded the most promising results 




Figure 39 Confocal microscopy images of the fibroblasts seeded on the electrospun and centrifugal spun 
scaffolds. The fibroblasts seed on the scaffolds were scanned on day 7 and day 17. ES PCL-1% PF-68 (ES1), ES PCL-5% 
PF-68 (ES5), ES PCL-10% PF-68 (ES10), ES PCL Control, CS PCL-1% PF-68 (CS1), CS PCL-5% PF-68 (CS5), CS PCL-
10% PF-68 (CS10), CS PCL Control. Green colour depicts the cellular biologic membranes (staining by DiOC6(3)), red 
colour cell nuclei (propidium iodide staining). Magnification 200x, scale bar 50 µm218. 
The data were confirmed by confocal microscopy. The fibroblast morphology detected on 
day 7 was similar on all the tested scaffolds. However, after a longer culture, the cell 
morphology among the scaffolds began to differ. On the scaffolds with the lower concentrations 
of PF-68, the cells were overlapped and more stratified. On the other hand, the cells on the 
scaffolds containing more of the platelet lyophilisate were more isolated and the boundaries 




Figure 40 SEM images of fibroblast morphology on the electrospun and the centrifugal spun scaffolds. The 
samples with the seeded cells were fixed and dehydrated on day 7 of the experiment. ES PCL-1% PF-68 (ES1), ES PCL-5% 
PF-68 (ES5), ES PCL-10% PF-68 (ES10), ES PCL Control, CS PCL-1% PF-68 (CS1), CS PCL-5% PF-68 (CS5), CS PCL-
10% PF-68 (CS10), CS PCL Control. Magnification 3000x, scale bar 20 µm218. 
Furthermore, the morphology of the seeded fibroblasts was visualised using scanning 
electron microscopy on day 7 (Figure 40). On the scaffolds with the lower platelet lyophilizate 
content, the cells formed clusters. However, with the increasing concentration of the platelet 
lyophilizate, the cells were well spread and exhibited morphology typical for the culture of 
fibroblasts on PCL scaffolds. To emphasize and more accurately observe the effect of the 
released platelet lyophilizate, the seeded cells were cultured under serum-reduced conditions 
(5% FBS), suggesting that the growth factors contained in scaffolds with lower concentration 
of platelet lyophilizate were not enough to properly stimulate fibroblast proliferation. 
The results indicate that the fibroblasts showed a similar growth pattern on both the 
electrospun and centrifugal spun scaffolds. Polycaprolactone in the form of fibrous scaffolds 
was shown to stimulate fibroblast proliferation and metabolic activity81,191. The results indicated 
a similar affinity of fibroblasts to both the nano-/microfibrous and microfibrous scaffolds. The 
126 
 
structure of both scaffolds resembled the structure of the ECM of the connective tissues and 
the fibroblasts showed good adhesion and proliferation on the scaffolds. In addition, the platelet 
lyophilizate stimulated cell metabolic activity in a rather dose-dependent manner, which was in 
accordance with our previous study91. The samples containing PF-68 and the lowest 
concentration of the growth factors did not significantly stimulate the cell metabolic activity. This 
may relate to the altered release characteristics or the dominant inhibitory effect of the released 
chemokines. The 1% PF-68 fibres showed the slowest release rate and the lowest total protein 
content. The most dominant chemokines in platelet lyophilizate were IL-17 and RANTES. At 
low concentrations, these proteins were the most abundant chemokines released from the 
fibres. IL-17 was shown to stimulate the production of pro-angiogenic factors in fibroblasts and 
thus mediate fibroblast-induced angiogenesis229. In the groups with higher PF-68 
concentrations, the amount of the total released protein was higher. With the increasing total 
protein concentration, the bioavailability of the growth factors, which act as fibroblast mitogens, 
increased as well (i.e. PDGF, EGF). Therefore, their proliferation and metabolic activity were 
improved. Such findings are in accordance with our previous study that revealed a dose-
dependent effect of human platelet lysate on fibroblasts cultured on plain electrospun PCL 
scaffolds172. Additionally, the positive effect of growth factors released from the platelets 
adhered to the PCL nanofibrous scaffold, was observed in fibroblast culture. 
6.4.5 Keratinocytes seeded on the fibrous scaffolds 
Additionally, keratinocytes were used to evaluate the biocompatibility of the prepared 




Figure 41 Metabolic activity and proliferation of keratinocytes seeded on the electrospun and centrifugal spun 
scaffolds. A – Metabolic activity of keratinocytes seeded on the electrospun scaffolds, B – Metabolic activity of keratinocytes 
seeded on the centrifugal spun scaffolds, C – Proliferation of keratinocytes seeded on the electrospun scaffolds, D – 
Proliferation of keratinocytes seeded on the centrifugal spun scaffolds. ES PCL-1% PF-68 (ES1), ES PCL-5% PF-68 (ES5), 
ES PCL-10% PF-68 (ES10), ES PCL Control, CS PCL-1% PF-68 (CS1), CS PCL-5% PF-68 (CS5), CS PCL-10% PF-68 
(CS10), CS PCL Control. D1 – D17 denote experimental days. The level of significance is denoted by the numbers above the 
bars in the graph, number 1 representing the E/CS1 scaffold, 2 the E/CS5 scaffold, 3 the E/CS10 scaffold and 4 the E/CS 
control scaffold Statistical significance was set at p<0.05218. 
The data acquired from keratinocytes seeded on the electrospun scaffolds (Figure 41A) 
showed improved metabolic activity on the ES5 and ES10 and ES Control samples, when 
compared to the ES1 scaffold through the first 14 days of the experiment. On day 14, the 
keratinocytes seeded on the ES5 sample showed improved metabolic activity when compared 
to the ES Control sample. Additionally, on day 17, the metabolic activity of keratinocytes seeded 
on the ES5 sample was significantly higher than all the other electrospun samples (ES1, ES10 
and ES Control). No such trend was observed on the centrifugal spun samples (Figure 41B). 
The samples CS5 and CS10 showed improved metabolic activity of the cells on days 1 and 3, 
however, all the differences were levelled out by day 7 and no statistically significant difference 
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in metabolic activity was observed until the end of the experiment. The performed overall 
statistical analysis of the metabolic activity of keratinocytes seeded on the fibrous samples 
showed, that on day 14 of the experiment the electrospun samples ES5, ES10 and the control 
sample exhibited higher metabolic activity of the seeded keratinocytes when compared to all 
the centrifugal spun samples (CS1, CS5, CS10 and CS Control). However, on the last day of 
the experiment, improved metabolic activity was found on the electrospun samples ES1 and 
ES5. 
Furthermore, keratinocyte proliferation was evaluated. The data showed increasing 
proliferation on the platelet lyophilisate-enriched electrospun scaffolds through the entire 
experiment (Figure 41C). On day 17, keratinocytes seeded on the ES5 scaffold showed 
superior proliferation to all the other electrospun samples. The proliferation of keratinocytes 
seeded on the centrifugal spun samples (Figure 41D) was not as pronounced as on the 
electrospun samples, and the stimulatory effect of platelet lyophilizate was not observed. 
The optimal concentration of the released bioactive molecules for keratinocyte culture 
seemed to follow the release pattern of fibrous scaffolds prepared with 5% PF-68. Keratinocytes 
cultured on such scaffolds showed a statistically significantly higher metabolic activity and cell 
proliferation, not only in comparison to the PCL control, but to the other platelet lyophilizate-
enriched samples as well. In our previous study with the platelets adhered to the surface of the 
nanofibres, all the platelet-functionalised PCL samples showed improved keratinocyte 
metabolic activity and proliferation without significant differences among them, suggesting the 
other concentrations of the platelet-derived bioactive molecules in the current study were either 
too high (ES10) and rather inhibited the keratinocyte proliferation, or too low (ES1) and, in terms 
of improved cellular proliferation, insufficient. The dose-dependent effect of platelet lyophilizate 
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in keratinocyte culture was also observed in culture on blend PCL nanofibers168. 
Correspondingly, we have investigated the optimal composition of cell culture media 
supplemented with platelet lysate (PL) in keratinocytes. According to our results, the stimulation 
of proliferation of keratinocytes was achieved with increasing PL concentration, with the optimal 
concentration being determined as 7% (v/v) PL172. 
 
Figure 42 Confocal microscopy images of the keratinocytes seeded on the electrospun and centrifugal spun 
scaffolds. The keratinocytes seed on the scaffolds were scanned on day 7 and day 17. ES PCL-1% PF-68 (ES1), ES PCL-
5% PF-68 (ES5), ES PCL-10% PF-68 (ES10), ES PCL Control, CS PCL-1% PF-68 (CS1), CS PCL-5% PF-68 (CS5), CS 
PCL-10% PF-68 (CS10), CS PCL Control. Green colour depicts the cellular biologic membranes (staining by DiOC6(3)), red 
colour cell nuclei (propidium iodide staining). Magnification 200x, scale bar 50 µm218. 
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The data obtained in the proliferation assay were confirmed by confocal microscopy (Figure 
42). The images acquired on day 17 showed significantly improved proliferation of 
keratinocytes on the ES5 sample, where the keratinocytes formed confluent layers and 
exhibited stratified morphology. Although the increase in cell numbers from day 7 to day 17 
was not so pronounced on the other samples (ES1, ES10, CS1, CS5, CS10 and controls), the 
proliferation of keratinocytes was clearly detectable. 
On the 2D-like electrospun samples, the cultured keratinocytes formed confluent layers. 
The most promising composition of the prepared fibres, in terms of promotion of stratified 
epithelium formation, was shown by the ES5 sample. Such findings confirmed that in favourable 
conditions, keratinocytes tend to mature, and form stratified layers. However, on all the 
centrifugal spun samples, islands varying in number of the cultured cells were found, regardless 
of the presence and/or concentration of the platelet-derived bioactive molecules. This indicates 
suboptimal morphology of the tested centrifugal spun fibrous layers for the stimulation of 
keratinocyte epithelium formation. Such findings are in concordance with the findings of study 
investigating the influence of fibre diameter and pore size of denatured collagen microfiber 
scaffolds on keratinocyte adhesion, proliferation, migration and penetration into the scaffold230. 
The results showed that the porous scaffold promoted cell adhesion and survival, however 
hampered keratinocyte migration and penetration. Thus, the data suggest suitability of the 
morphology of the electrospun layers for keratinocyte stimulation. 
Additionally, scanning electron microscopy was used to visualise the cells adhered to the 
nanofibrous scaffolds on day 7 (Figure 43). The images showed well spread cells with 




Figure 43 SEM images of keratinocyte morphology on the electrospun and the centrifugal spun scaffolds. The 
samples with the seeded cells were fixed and dehydrated on day 7 of the experiment. ES PCL-1% PF-68 (ES1), ES PCL-5% 
PF-68 (ES5), ES PCL-10% PF-68 (ES10), ES PCL Control, CS PCL-1% PF-68 (CS1), CS PCL-5% PF-68 (CS5), CS PCL-
10% PF-68 (CS10), CS PCL Control. Magnification 3000x, scale bar 20 µm218. 
On the electrospun scaffolds, the cells were observed on the surface of the fibres. The 
structure of the scaffold was mimicking the basal lamina. On the other hand, in the case of 
centrifugal spun scaffolds, the bigger pore size lead to formation of clusters and spheroid like 
structures. The cells were less spread, and the colonisation of the scaffold was relatively slower. 
This phenomenon was associated with the different structure of the scaffold. The scaffold with 
a smaller pore size supported cell adhesion but did not allow cell penetration into its deeper 
layers, stimulating only cell interaction on superficial layers and pushing the cells to more 
epithelial tissue formation. 
The superior morphological properties of the nanofibres compared to microfibres were 
shown in chitin electrospun fibrous scaffolds and silk fibroin matrices231,232. The submicron 
diameters of the nanofibrous scaffolds significantly promoted cell adhesion and spreading, 
compared to the microfibres. Additionally, the dependency of keratinocyte proliferation on the 
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strand diameter of 3D-plotted collagen fibres was investigated. With the increasing strand 
diameter, the proliferation rate of keratinocytes decreased233. This indicates the importance of 
proper morphology of the fibrous scaffolds in skin tissue engineering constructs. 
Besides morphological mimicking, the release of growth factors stimulated cell proliferation. 
Human keratinocytes were cultured on PCL and PCL/collagen blend electrospun nanofibrous 
matrices with immobilised EGF on their surface. The nanofibrous texture of the scaffolds 
affected the cultured cells. Furthermore, the drug delivery of the immobilised EGF to the surface 
of the nanofibres resulted in rapid proliferation of keratinocytes in comparison to the control 
samples containing no EGF79. Another study showed that the bioavailability of EGF in an animal 
diabetic wound model was prolonged by its conjugation to the surface of the PCL/PEG 
nanofibrous scaffolds in comparison to the PCL/PEG nanofibres soaked in the EGF solution. 
Such treatment accelerated the wound closure, especially in its early stages95. These studies 
have illustrated the necessity of a sustained release of the growth factors, as most of the GFs 
administered as exogenous additives failed in clinical practice, mainly due to the high proteolytic 
activities in the wound. 
6.4.6 Summary 
The developed drug delivery system enabled long-term delivery of susceptible molecules; 
significant levels of proteins were detected even after a period of 1 month. Furthermore, a 
comparable loading efficiency was achieved with the electrostatic and centrifugal spinning 
techniques. By alteration of the concentration of the core polymer, the release rate may be 
adjusted to the particular application. The prepared systems were tested in vitro. The data 
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showed both the 3D- and 2D-like systems were able to foster fibroblast culture, however, 




Tissue engineering is a rapidly evolving field, flexibly responding to the unmet needs of the 
current medicine. The presented thesis aimed to explore the possibilities of utilization of platelet 
derivatives in the tissue engineering of the skin. 
Firstly, the skin cell culture conditions were optimized, as there is a need for FBS 
replacement in clinical applications, to prevent xenogeneic immunization. It was shown that 7% 
platelet lysate sufficiently replaced the effects of 10% FBS. Interestingly, different cells 
responded to increased or decreased concentrations of bioactive molecules in a different way. 
While fibroblasts preferred lower concentrations with rather inhibitory effects of combination of 
FBS and platelet lysate, keratinocytes responded positively to the increasing concentrations of 
bioactive molecules. This finding highlights the necessity for optimization of cell culture 
conditions in clinical settings. 
Furthermore, a drug delivery system suitable as a wound dressing was developed and 
optimized. The surface adhesion of autologous platelets in combination with the unique 
properties of nanofibres enables the translation of such system into clinical practice for topical 
applications. By adjusting the properties of the system, a scaffold delivering bioactive molecules 
crucial for fostering the healing process for up to 2 weeks was developed. Achieving such time 
frame for bioactive molecule delivery is remarkable, considering the simplicity of the system 
enabling its on-site preparation. The system represents a bridge between basic research and 
clinical application. 
The short life span of native platelet derivatives was overcome by using the platelet 
lyophilisate. Lyophilisation of the platelets prolongs their life span from five days to up to two 
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years. Furthermore, it facilitates loading of the platelet content into drug delivery systems, 
ranging from surface modifications to encapsulation. Given the contained growth factors and 
their distinct role in the healing process, it is a versatile system that could find broader 
application in tissue engineering, not only in tissue engineering of the skin. The improved 




Platelet derivatives are an attractive source of natural growth factors and they are widely 
used in various tissue engineering and regenerative medicine applications. 
The aim of this study was to optimize cell culture conditions using platelet lysate and to 
develop platelet-functionalized fibrous scaffolds as a controlled drug delivery system for native 
growth factors. Fibrous scaffolds were prepared by electrostatic and centrifugal spinning of PCL 
and they were functionalized by the platelets by surface adhesion or their encapsulation using 
emulsion spinning techniques. 
The cell culture study determined the 7% platelet lysate to be the optimum concentration 
as a medium supplement in keratinocyte and fibroblast culture. Additionally, following surface 
adhesion of the platelets to PCL electrospun nanofibres, the platelets were activated due to 
their contact with the nanofibre nanotopography, resulting in formation of fibrin network. Fibrin 
served as a reservoir of the growth factors, prolonging the half-time of EGF release to 1.7 days. 
Such platelet-functionalized samples fostered proliferation of keratinocytes, fibroblasts and 
melanocytes. Furthermore, adhesion of platelets to centrifugally spun nanofibrous scaffolds 
resulted in almost two-fold increase in the amount of immobilized platelet-derived bioactive 
molecules, further promoting metabolic activity of the seeded melanocytes. Thanks to 
encapsulation of the platelet lyophilisate into emulsion electrospun and centrifugal spun coaxial 
nanofibres, a drug delivery system enabling long-term delivery of platelet-derive biomolecules 
was developed and optimized. The system was successfully tested in vitro using keratinocytes 




Krevní deriváty jsou výborným zdrojem přirozených růstových faktorů. V tkáňovém 
inženýrství a regenerativní medicíně již našly řadu uplatnění. 
Cílem této práce bylo optimalizovat podmínky buněčné kultury za použití destičkového 
lyzátu, a dále vyvinout mikro- a nanovlákenné nosiče funkcionalizované krevními destičkami, 
které by mohly sloužit jako systém řízeného dodávání přírodních růstových faktorů. Mikro- a 
nanovlákenné nosiče byly připraveny elektrostatickým a centrifugačním zvlákňováním PCL. 
Připravené nosiče byly funkcionalizovány povrchovou adhezí krevních destiček nebo jejich 
enkapsulací do vnitřní části nanovláken emulzní technikou. 
V rámci studie kultivačních podmínek kožních buněk bylo zjištěno, že suplementace media 
7% destičkovým lyzátem je dostačující pro nahrazení 10% FBS v kultuře keratinocytů a 
fibroblastů. Dále byl povrch PCL nanovláken připravených elektrostatickým zvlákňováním 
funkcionalizován krevními destičkami. Při kontaktu s nanotopografií nanovlákenného povrchu 
došlo k aktivaci destiček a následně k vytvoření fibrinové sítě, která sloužila jako rezervoár 
růstových faktorů. Díky tomu došlo k prodloužení poločasu uvolnění EGF až na 1.7 dní. Takto 
funkcionalizované nanovlákenné nosiče podporovaly proliferace a metabolickou aktivitu 
keratinocytů, fibroblastů a melanocytů. Při adhezi krevních destiček na mikro-/nanovlákna 
vytvořená centrifugačním zvlákňováním došlo k dvounásobnému nárůstu množství růstových 
faktorů zachycených na nosiči, a následně k další stimulaci metabolické aktivity nasazených 
melanocytů. Díky enkapsulaci destičkového lyofilizátu do koaxiálních nanovláken byl vytvořen 
systém dlouhodobého dodávání, který byl otestován pomocí fibroblastů a keratinocytů. Díky 
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